Immune responses to BK polyomavirus in healthy donors and renal transplant recipients by Fallatah, Deema









Immune responses to BK polyomavirus in healthy donors 







PhD student /virology  




Prof William Paxton 
Dr Steve Christmas 
Dr Ian Hart  
Dr Georgios Pollakis 
  
Department of Clinical Infection, Microbiology & 
Immunology, Institute of Infection and Global Health, The 
Ronald Ross Building 
The University of Liverpool 
2020 










I, Nafraa Fallatah, declare that this thesis represents my own work which has been done 
after registration for the PhD degree at University of Liverpool, and has not been 
previously included in a thesis or dissertation submitted to this or any other institution 









Signature:     Nafraa F                                                                                                                              Date: 
  






Background: BKV is a human polyomavirus, a member of the Polyomaviridae 
family that includes JC virus and SV40. Within the general population the virus 
infects the host with no clear symptoms displayed by infected individuals. The 
virus possesses a high seroprevalence reaching 80% within the general 
population and with more than 19% of healthy subjects shedding BK virus in 
their urine. After primary infection, which is mainly sub-clinical, the virus 
persists in the urinary tissue and establishes latency. In immunocompetent 
individuals the virus persists in the urinary and renal epithelium in its established 
latent form. However, in individuals with impaired immune surveillance such as 
in patients receiving immune-suppressive therapies, as prescribed following 
organ transplant, the virus can reactivate. In kidney transplant recipients (KTR), 
30-40% of patients develop BKV viremia while 1-10% progress to BK virus 
nephropathy. This project investigated host cellular and humoral immune 
responses to BK virus and to monitor viral genotypes in infected individuals and 
correlate these variant parameters with disease severity and progression.  
Methods: Urine, plasma, and PBMCs were collected from post kidney transplant 
recipients and healthy volunteers. Real-time PCR was used to identify subjects 
secreting BKV in their urine and sandwich ELISAs used to measure BK-specific 
immunoglobulin G antibody and soluble HLA-G levels in serum samples from 
healthy and post kidney transplant recipients. To detect cellular immune 
responses mounted against BKV, INF-γ secreting cells were quantified and HLA-
G expression was measured using ELISPOT and surface staining assays, 
respectively. A nested PCR assay was developed and used to identify BKV 
genotypes among patients.   
Results: BKV specific cellular immune responses were compared between 
healthy subjects and those where BKV was identified in urine. 
Immunocompetent subjects with detected virus showed higher cellular 
responses than negative subjects, while in immunocompromised KTR individuals 
receiving immunosuppressive therapy it was identified that the presence of 
virus, as detected by viral DNA, was associated with the induction of anti BKV 
IgG responses but did not associate with the induction of BKV specific cellular 
immune responses. However, when immune-suppressive therapies were reduced 
cellular immune responses were found to be restored. 
Investigation of HLA-G cell surface protein expression on PBMCs of patients with 
BKV infection suggested that monocytes expressed more HLA-G than other 
leucocyte subsets. Additionally, patients with active BKV infection showed 
dramatic increases in soluble HLA-G expression levels in plasma in comparison 
to the control group, while no difference was observed in soluble HLA-G levels 
between the KTR groups tested. 




Pre-transplant anti BKV IgG levels were similar in patients with post-transplant 
BK viremia and those who never demonstrated BKV viremia. The level was 
stable in BKV negative patients during follow up, whilst in viremic patients a 
significant increase in BKV IgG levels associated with development of viremia in 
parallel with reduction in immunosuppressive therapy. Further, we observed that 
the presence of HLA-B44 and HLA-DR15 was significantly associated with 
increased risk of viremia among the recipients. 
Finally, by studying the influence of BKV genotypes on development of viremia, 
genotype lb-2 was found to be the most prevalent genotype among our patients, 
with no observed significant correlation between genotype and incidence of BKV 
viremia. 
 
In conclusion: BKV cellular immune responses, without a detectable level of 
anti-BKV antibodies, could be associated with protection against BKV 
reactivation. Moreover, HLA-G expression on some immune cellular subsets 
increased after primary virus infection and may play a role in virus immune 
evasion during infection. Pre-transplant anti BKV IgG responses could not predict 
the risk of post-transplant viremia. Kidney transplant recipient individuals with 
HLA-B44 and HLA-DR15 alleles were shown to be more susceptible to developing 
BKV viremia. The majority of BKV patients were shown to be infected with the 
Ib-2 genotype and no differences were found between virus genotype and 
virulence.  
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1  Introduction and background  
 
Introduction 
BKV is a member of the polyomavirus family similar to other polyomaviruses such 
as JC virus and SV40 virus, which are closely related to BKV (Figure 1.1). The 
virus is mainly acquired in early childhood with no symptoms or flu like symptoms 
shown (G. R. Ambalathingal, R. S. Francis, M. J. Smyth, C. Smith, & R. Khanna, 
2017; W. A. Knowles, 2006); in the presence of proper immune surveillance, it 
then establishes latency with transient low levels of urinary shedding.  
In immunocompromised patients, such as renal transplant recipients, BKV 
reactivates due to the introduction of immune suppressive drugs that weaken host 
immunity. In fact, the lack of proper immunity leads to the host’s inability to 
control BKV replication, induction of BKV viremia often leading to polyomavirus-
associated nephropathy (BKyAN) (H. H. Hirsch et al., 2005; Reploeg, Storch, & 
Clifford, 2001). 
Yet, forty years after discovery of the virus, no effective antivirus treatment is 
approved for BKV associated disease (Bridges, Donegan, & Badros, 2006; Ganguly 
et al., 2010; Snydman et al., 2002). The only management strategy in most 
kidney transplant centres is reduction of immunosuppressive treatments in order 
to retain some of the host immunity while taking care to avoid graft rejection. This 
raises the need of better understanding of BKV pathogenesis and the host 
immunity mechanism controlling virus replication and development of effective 
treatments that prevent BKV disease and loss of graft following kidney transplant. 
BKV reactivation in renal recipient is still puzzling transplant physicians. since 
1971, several studies have tried to demonstrate recipient BKV reactivation risk 
factors to identify those that could be eliminated or modified pre-transplant. 
Unfortunately, there is conflict and inconsistency within the literature.  
Here, we studied immune responses induced against BKV in immunocompetent 
subjects and renal transplant recipients. In addition, we considered the pre-
transplant risk factors that may influence or eliminate viral replication after 
transplantation, aiming to identify risk factors, monitoring and modification 





Figure 1.1. Phylogenetic tree of the polyomavirus family.  
• Phylogenetic tree Contains all polyomavirus species know11502007541150200754n until 
June 2014, including  Human polyomaviruses highlighted in red (From(Herman F Wunderink 




1.1  The virus  
1.1.1 BKV history 
The polyomavirus family was accidentally discovered in 1953 by Ludwig Gross 
while studying murine leukaemia virus (MLV) and named as polyomaviruses due 
to their ability to cause multiple(poly)tumours (oma) in mice (Gross, 1953; 
Krumbholz, Bininda-Emonds, Wutzler, & Zell, 2009). Before 1999, polyomaviruses 
were classified under Papovaviridae that includes human papillomaviruses until 
they were reclassified into a separate family polyomaviridae (Feltkamp, Kazem, 
van der Meijden, Lauber, & Gorbalenya, 2013). The family of Polyomaviridae 
includes more than 30 species of viruses; only thirteen of them infect humans, 




trichodysplasia spinulosa-associated polyomavirus, and NJ (Lamarche et al., 
2016). Twelve of them were isolated in the period between 2007-2017 (Gheit et 
al., 2017; Korup et al., 2013; Lim et al., 2013; Mishra et al., 2014). 
BK polyomavirus was discovered in 1971 in London from a urine sample of a 
transplant recipient who received a kidney from his brother. Initially, the agent 
was mistaken for a wart virus, however after inoculating the agent in cell culture 
and evaluating its cytopathic effects (CPE) the isolate was identified as BKV, after 
the initials of the patient (S. D. Gardner, Field, Coleman, & Hulme, 1971).     
 
1.1.2 Virion and Genome 
Polyomaviruses are small non-enveloped viruses with a major capsid protein 
called VP1; the virion consists of 72 pentameric VP1 capsomers arranged in T=7 
that form an icosahedral structure. The VP1 protein is essential for virus entry by 
attaching to the host receptors (Hurdiss D  et al., 2016; Liddington et al., 1991). 
Deep inside the capsid, there are additionally two minor proteins VP2 and VP3 
which are believed to result in genome packaging into the virion, virus uncoating 
and delivery to the host nucleus (Shishido-Hara, Ichinose, Higuchi, Hara, & Yasui, 
2004) (Figure 1.2).  
The capsid proteins are encoded by a circular dsDNA genome of 5100-5300bp that  
can resist heat up to 50 °C for 30min with major effects on its infectivity (Alalawi, 
Kossi, Jenkins, & Halawa, 2020) and divided into three functional regions; first, 
the non-coding control region (NCCR), hypervariable region that includes different 
binding sites that aid in the initiation and regulation of the other regions’ 
transcription. It also includes a hypervariable regulatory region (HVRR) that is 
divided into five consecutive blocks; O-P-Q-R-S O142, P68, Q39, R63, and S63, 
where the numbers indicate the sequence length in bp (Olsen et al, 2009; Figure 
1.3).  
Second, the early coding region is approximately 2400 bp in length and encodes 
for a large tumour antigen (TAg) as well as a small tumour antigen (tAg) that 
accumulate in the nucleus to help in virus replication. During virus replication, TAg 
generates a complex that binds to the ori and facilitates transcription of the late 
coding region, while tAg also aids in viral replication, cell cycle progression and 




2008; Rinaldo, Tylden, & Sharma, 2013). Additionally, it is worth mentioning that 
all polyomaviruses do not encode a viral DNA polymerase enzyme, but completely 
rely on enzymes and transcription factors of the host and expressed in infected 
cells. Therefore, activated cell signals and growth factors are essential for virus 
replication (Khalili & Stoner, 2004). 
Finally, the late coding region is approximately 2300 bp in size and includes genes 
encoding the virus’s three structural proteins VP1, VP2 and VP3 in addition to the 
non-structural protein agnoprotein that is only found in BKV and SV40. 
 
Figure 1.2. Polyomavirus BK structure 
 VP1 major capsid protein and VP2, VP3 proteins surrounding the dsDNA molecule. Adapted from Helle et al., (2017). 
 
 
1.1.3 Genotypes and subtypes  
Based on nucleotide sequence analysis of genomes from all isolates, BKV was 
classified into four main genotypes (I-IV). Subtype I is considered as the most 
prevalent genotype with approximately 80% distribution worldwide, followed by 
subtype IV with 15% distribution and being mainly detected in Asia while the other 
subtypes are rarely found. However, due to BKV diversity and difficulties in 
identifying viral strains into the mentioned groupings, additional sub-
categorisation was needed within the original four genotypes (Pastrana et al., 
2013).   
Based on the phylogenetic tree analysis subtype I can be divided into four 
subgroups: Ia, Ib-1, Ib-2 and Ic. Subtype IV is sub-typed into six different 




may have an impact on development of BKVN in kidney transplant recipients. In 
Japan, a study in 2004 found that most BKV genotypes isolated from renal 
transplant recipients were subgroup I, while samples from bone marrow transplant 
recipients were identified as belonging to genotype Ic (Takasaka et al., 2004). 
Moreover, it has been noticed that some BKV genotypes show different virus 
properties in vitro; some variants exhibit a greater cytopathic effect than others 
(Tremolada et al., 2010), but it is still unclear whether some genotypes could 
possess biological properties that may influence progression of BKV nephropathy 
in post kidney transplant recipients. A study by Schwarz et al, found that BKV 
subtype IV may influence progression of BKVN (Schwarz et al., 2016). 
Furthermore, in Brazil, Rafael and colleges proposed that the BKV 1a genotype 
may have a potential risk associated with BKVN progression (R. B. Varella, Zalona, 
Diaz, Zalis, & Santoro-Lopes, 2018). 
Even though there is not enough supporting evidence, BKV genotype diversity 
could be linked to its geographical distribution with different cellular tropisms or 
even pathological impacts and where genotypes could correlate with specific 
diseases. 
A previous study demonstrated a link between human populations and BKV 
subtype I subgroups (Ib-2 and Ic); it suggested that subgroup Ib-2 is widespread 
among Europeans, whereas Ic is more restricted to north-east Asians, with the 
findings indicating a possible geographical separation of European and Asian BKV 
strains (Ikegaya et al., 2006). Moreover, there is different classification of BK virus 
variants based on the sequence diversity within the NCCR region, rearranged (rr) 
and archetype (ww) (Olsen, Hirsch, & Rinaldo, 2009). Ultimately, further work is 







Figure 1.3. BKV genome organization. 
The transcription of both early and late coding regions proceeds in a bidirectional way from the origin of replication (ORI) 
within the noncoding control region (NCCR) The late coding regions encode structural proteins (VP1, VP2, and VP3), in addition 
to the non-immunogenic agnoprotein, whereas, the early coding regions transcribe the tumorigenic proteins (LTA and STA) 




1.1.4 Life cycle 
Unlike other polyomaviruses that utilise clathrin-mediated viral entry, BKV invades 
the target cell via caveolae-mediated endocytosis to reach the cytoplasmic 
reticulum (CR) by using 2 ganglioside receptors: GT1b and GD1b to bind to host 
cells; these receptors are present on kidney and urinary tract cells making them 
the main sites of viral infection and replication (Zaman, Ettenger, Cheam, 
Malekzadeh, & Tsai, 2014) (Figure 1.5). In the CR the virus is partially uncoated 
by reduction and isomerization of VP1 protein disulphide bonds. Subsequently, the 
virion translocates to the cytosol using microtubules and transits through the 




To pass through the nuclear pore (40-45 nm), the virion must be partially 
disassembled into approximately 39 nm size particles. After viral DNA entry to the 
host cell nucleus via the nuclear pore complex (Yogo, Sugimoto, Zhong, & Homma, 
2009), it either starts replication or proceeds to latency; in fact this next step is 
dependent on the host cellular immune status. 
Regarding replication, the virus DNA initiates transcription of both the LTag and 
sTag genes (Kean, Rao, Wang, & Garcea, 2009), followed by Late genes that 
encode for the structural proteins and transcription of VP1, VP2 and VP3 (H. H. 
Hirsch & Steiger, 2003). After assembly of the capsid with newly synthesized DNA, 













Figure 1.4.BKV genotypes and subtypes  








Figure 1.5. BKV replication cycle 
Entry, both early and late gene expression and virus particle assembly and release. 1. BKV virion attachment to the ganglioside 
receptors at the cell surface. 2. Host cell entry through a caveola-mediated endocytosis. 3. 10 h post-infection the virus 
transfers from the late endosomes to the endoplasmic reticulum (ER). 4. Partial capsid uncoating in ER. 5. Viral genome 
transport into the nucleus via the nuclear pore complex using VP2/VP3 NLS and the importin α/β1 import pathway. 6. 
Approximately 24 h post-infection, early gene expression begins. 7. Translocation of the early proteins into the nucleus for 
DNA replication. 8. Late gene expression. 9. Translocation of late proteins into the nucleus for assembly. 10. Virions release 
from infected cells after cell lysis. 11. Some virions may be released into the extracellular environment through a non-lytic 
egress that depends on the cellular secretion pathway. [Adapted from (Helle et al., 2017) 
 
 
1.2  Epidemiology and transmission 
The discovery of BK virus was serendipitous. Unexpectedly, a large number of 
papovavirus particles were found in a patient’s urine sample that had been 
collected more than three months post-transplant, and many inclusion–bearing 
cells had been seen, which confirmed the presence of papovavirus. Later, 
inoculation of the virus into a culture of secondary monkey fibroblasts provided 
excellent confirmation of a cytopathic effect and resulting in the identification of 




BK virus is an endemic, non-seasonal, ubiquitous virus which is not related to the 
socio-economic status of the individual. Primary infection results in either a 
subclinical infection or sometimes associates with mild flu-like symptoms; after 
primary infection in immunocompetent subjects, the virus persists and establishes 
latency. It is unknown whether the virus is truly latent or just demonstrates low 
levels of gene expression.  
Based on age at time of antibody seroconversion, the virus is found to be mainly 
acquired and transmitted between children; a study found that the virus was 
transmitted  more in children who attended nurseries  in comparison to  those 
who stayed at home (Mantyjarvi, Meurman, Vihma, & Berglund, 1973). The 
primary route of BKV transmission is via direct contact (mostly in children) 
(Goudsmit, Dillen, Van Strien, & Van der Noordaa, 1982). Additionally, other 
routes were proposed, such as sexually through semen, urine in 
immunocompromised and pregnant women due to virus replication in the urinary 
tract and the faecal–oral route (Jiang, Abend, Johnson, & Imperiale, 2009). 
Congenital transmission is also predicted as BK virus IgM antibodies were found 
in cord blood samples, brain and kidney samplings of an aborted foetus and urine 
of a one-month old baby, which suggests reactivation or primary infection of BK 
virus during pregnancy (Taguchi, Nagaki, Saito, Haruyama, & Iwasaki, 1975). 
Blood-borne transmission of BKV was also indicated and it is worth mentioning 
that soiled water is the first suspect in BK virus infection (Jiang et al., 2009; 
Siguier, Sellier, & Bergmann, 2012).  
BKV was found globally, in both developed and developing countries, as confirmed 
from many epidemiological studies (Wendy A Knowles, 2001; Ocampo, Rosso, 
Pacheco, & Villegas, 2017), except in some populations where the prevalence is 
0% which means complete absence of BK virus in remote areas such as some 
aboriginal tribes in Brazil, Malaysia and India (W. A. Knowles, 2006). 
 
1.2.1  Epidemiology in immunocompetent subjects 
Overall BK virus seroprevalence within the human population reaches up to 90%. 
However, the number of seropositive individuals starts to decrease slightly after 
the age of 40 years (Kean et al., 2009; W. A. Knowles et al., 2003). In the general 




old, whilst in infants less than two years old antibodies are acquired from the 
mother. Infection gradually drops with age to 70-80% in adults (40-60) years, 
which may explain the lack of ongoing antigenic stimulation in most of the adults. 
Asymptomatic urinary shedding of BKV occurs in up to 62% of healthy BKV-
seropositive individuals (H. H. Hirsch & Steiger, 2003; Ling et al., 2003; 
Sundsfjord et al., 1999), yet the reason behind the shedding is not well 
understood, unless it could be a consequence of periodic viral reactivation. 
Anti-virus IgM antibodies were detected in children aged 2-5 years old, but it is 
rare to detect IgM in adult samples; some studies reported IgM antibodies in 19% 
of adult sera. A possible explanation of these rare findings may be differences in 
the sensitivity and specificity of the methods used in antibody detection. However, 
it is hard to confirm whether the IgM is a result of primary BK infection or re-
infection (W. A. Knowles, 2006). 
Generally, there is no difference in BKV seroprevalence in relation to gender. The 
importance of antibody prevalence as a part of BK virus diagnosis lies in its 
stability. BK antibody levels could remain stable for more than 11 years, in other 
words, long-lived memory B cells which make it a reliable and reasonable 
parameter in PyV disease and infection (Antonsson et al., 2010). Understanding 
the humoral immune response against BKV is an essential tool in choosing the 
best candidate for transplant donation.  
 
1.2.2  Epidemiology in immunocompromised patients 
BKV was first isolated from urine of a kidney transplant recipient who was suffering 
from ureteral fibrosis and obstruction after transplant. Subsequently, four years 
after discovery of the virus, the virus antigen was detected utilising an indirect 
immunofluorescence assay with urine of 3 patients who received chemotherapy to 
treat their malignancies in 1975 (Reese, Reissig, Daniel, & Shah, 1975). 
As mentioned previously, asymptomatic BKV shedding in urine of healthy 
individuals reaches up to 62%. However, in patients with supressed immunity 
such as post kidney transplant recipients, latent virus reactivation could lead to 
viremia and significant renal and urinary tract pathology, nephropathy, ureteral 




The prevalence of BK viruria in renal transplant recipients has been found to be 
between 30–57% (Adrian Egli et al., 2009). Even though the viruria does not 
necessary lead to the development of BKV disease it causes viremia in 5-30% of 
renal transplant recipients and the frequency of BKV nephropathy is reported to 
be 1–10%, mainly in recipients with sustained viremia or high viral loads and 
whom are diagnosed at an average of 24 weeks post-transplant (H. H. Hirsch & 
Steiger, 2003).  
 
1.3 Pathophysiology 
In healthy individuals, it is believed that BKV infects the respiratory tract in 
childhood, then goes latent in the urinary tract (uro-epithelial cells; (W. A. Knowles 
et al., 2003). However, following any immunosuppression or absence of immune 
surveillance, the virus activates and replicates in the distal tubule epithelial cells, 
which may lead to inflammation, tissue damage and unfolding of the tubular 
basement membrane. This tissue necrosis event leads to viral spread in 
intratubular spaces and peritubular capillaries then to adjacent cells, resulting in 
active infection and progression of BKN and ureteric stenosis (Fig 1.6). Moreover, 
Zeng and colleagues proposed that some miRNAs from virus infected cells, such 
as tubular epithelial cells, may regulate the BKV life cycle and help in host immune 
evasion (Zeng et al., 2019). Asymptomatic urinary shedding was detected in 7% 
of immunocompetent subjects, with a median viral load of 4.64 log copies/mL (A. 
Egli et al., 2009), while it is rare to observe virus DNA in healthy donors’ plasma. 
After kidney transplantation, due to the induction of immunosuppression therapy 
and reduction of immunity as a consequence, 30% of recipients were found to 
shed virus, with 1-10% of those developing BKN and 50-80% of the BKN patients 
losing their grafted kidney within two years post viral detection (Yi, Knight, & 
Lunsford, 2017) (Figure 1.6). BKVAN has been increasingly detected for the past 
10–15 years in post kidney transplant recipients. Moreover, the virus is known to 
cause haemorrhagic cystitis, pneumonia, meningoencephalitis and retinitis. 
Furthermore, it has been reported to cause reno-urinary neoplasms (Alexiev et 





Figure 1.6. BKV virus disease progression 
 Development  of BKV disease from latency in immunocompetent hosts (top) to reactivation and BKPyAN in 




1.4  Immune responses to viral infections 
It is well known that most vertebrates have developed mechanisms to induce  
immune responses targeted against foreign antigen and this immunity is 
completely dependent on discriminating self from non-self-proteins (Janeway Jr, 




as viruses, immune recognition goes through two separate strategies: the 
stimulation of innate as well as adaptive immune responses. The innate immune 
response is considered as the first line of defence against microorganisms, which 
produce an immediate non-antigen-specific response but without immunological 
memory, whereas the adaptive immune response is more specific and delayed. It 
induces antigenic specific responses against the invading pathogen with 
development of immunological memory (Janeway, 2001).  
 
1.4.1 Innate immune defences 
The body’s innate immunity starts before the microorganism invades the internal 
system. Anatomic barriers like skin, mucosa or surfaces within the body, such as 
endothelial cells and basement membranes, are the first obstacles that prevent 
viruses from penetrating the body (Janeway Jr & Medzhitov, 2002). Additionally, 
in the gastrointestinal tract, some viruses can be digested and inactivated by 
gastric acid, bile salts and enzymes (Weiss, 1985; Veloso Alves Pereira, 2015). 
Furthermore, most body fluids and tissues contain an array of viral inhibitors that 
prevent viral attachment or inhibit virus infection (Pfaender et al., 2013).  
In most viral infections, the immunocompetent host takes the opportunity to 
attack the virus before reaching the cells. However, if the virus manages to defeat 
the above obstacles and penetrates cells, it will be recognised by the immune 
system. That consists of a complex network of cells and soluble molecules that 
are induced in response to non-self-antigen recognition. Various soluble 
molecules, e.g. pentraxins, lectins, ficolins and also some non-immunological 
molecules participating in inhibitory functions against microbes like transferrin and 
lactoferrin (Kariminik, Yaghobi, & Dabiri, 2016). More importantly, type 1 
interferons are considered as key molecules in the innate defence response 
against viruses, due to their strong anti-viral activities by activating gene 
expression of many antiviral proteins such as; TNF-alpha, Fas/FasL, caspase-4, 
caspase-8, dsRNA activated protein kinase (PKR), death activating protein kinases 
(DAP kinase; (Chawla-Sarkar et al., 2003). Also, it activates natural killer (NK) 
cells and dendritic cells (DCs) that initiate the adaptive immune response and give 
the infected cell a transitory resistance phenotype (Le Bon & Tough, 2002). 




intrinsic immunity; it is an interferon (INF)-independent antiviral response that is 
mediated by expressed cellular proteins (so-called intrinsic host restriction 
factors), these factors act immediately to control viral gene expression (Boutell & 
Everett, 2013).  
Generally, the main cellular players of innate immunity targeting viral infections 
are monocytes, DCs, NK (the most important), neutrophils, eosinophils, basophils 
and mast cells. These cells are responsible for expression of a set of germlines 
encoded pattern recognition receptors (PRRs); these receptors are able to 
recognize conserved molecular patterns associated with viruses and trigger an 
immediate inflammatory response by production of pro-inflammatory cytokines 
and chemokines (Janeway Jr & Medzhitov, 2002; Kawai & Akira, 2007; Medzhitov, 
2007).  
DCs are antigen-presenting cells, and the main function of these cells is antigen 
processing and presentation at the cell surface where they act as a vehicle linking 
the innate and the adaptive immune responses. In post kidney transplant and 
immunosuppressed patients, DC levels in the peripheral blood drop significantly 
with greater reduction in plasmacytoid DCs. This drop may last up to three months 
after transplantation but due to the immunosuppression the deficiency could last 
longer in recipients (Hesselink et al., 2005). Therefore, any reduction in DC 
populations in peripheral blood will lead to reduction in virus antigen presentation 
and lack of activated specific T-cells being induced against the virus which may 
result in increased virus replication. As a result, Drake and colleagues, using a 
mouse model, found  that elevation of DC numbers is directly proportional to the 
enhancement of virus specific CD8+ T cells (Drake et al., 2001). Despite the 
mechanism of DC activation after BKV infections not being completely understood, 
previous studies suggested the important role of DCs in induction of the adaptive 
immune response and generation of T-cells specific to BKV (G. R. Ambalathingal 
et al., 2017). 
NK cells are another crucial component of innate immunity during viral infections. 
The role of NK cells and their activation mechanism are not yet well understood. 
NK function is mainly controlled by a balance of activating and inhibitory signals 
provided by killer-cell immunoglobulin-like receptors (KIRs) through the 




reduction of HLA expression is believed to increase NK cell activation. In addition, 
in antibody-dependent cellular cytotoxicity (ADCC) NK Receptors FcγRIIIA and/or 
FcγRIIIC bind to the Fc portions of antibodies bound to target cells, which leads 
to NK activation (Rouse & Mueller, 2019). Further, some cytokines and other 
receptors such as the NKG2 family may enhance NK cell activation and signalling. 
Furthermore, it has been proposed that some non-classical HLA molecules, such 
as HLA-G have an inhibitory effect on NK cells at the maternal/fetal interface by 
protecting the foetus from attack by NK cells of the mother (Carosella, Favier, 
Rouas-Freiss, Moreau, & LeMaoult, 2008). However, other reports found that the 
inhibitory effect of HLA-G was due to T-cells and not NK cells (Van der Meer et al., 
2007). In some viral infections such as CMV, the virus produces some proteins 
that target HLA class I molecules and prevent antigen presentation on the infected 
cells. However, some of these virus proteins may differentiate between classical 
and non- classical HLA molecules, while others effect both types. Studying the 
effect of HLA-G on evasion of anti-viral immunity is essential to understanding its 
effect on viral reactivation. 
Trydzenskaya et al. highlighted the role of KIRs in controlling BK infection. Patients 
with BKVN were found to have a lower number of KIRs compared with controls 
(Trydzenskaya et al., 2013). The same group also reported a significant drop in 
KIR3DS1 of NK cells in patients with BKAN and in BK-reactivated patients when 
comparing to controls group (Trydzenskaya et al., 2013). Interestingly, viruses 
have developed many strategies to evade recognition by NK cells (Figure 1.7), 
such as BKV miRNA that mediates downregulation of the NKG2D ligand. Also, a 
correlation has been observed between KIR genotypes and CMV infection in post 
kidney transplant recipients. A combination of activating receptor (KIR2DS2) and 
inhibitory receptor (KIR2DL3) was observed to be associated with protection 
against CMV viremia (van Duin, 2014). A different study reported a significant 
reduction of CMV viremia in kidney transplant recipients with KIR B haplotypes 





Figure 1.7. BKV mechanism in evading NK cell activity 
 The virus inhibits the expression of activator molecules on the virus infected cell, also encourages it to produce transforming 






1.4.2  Adaptive responses 
The initiation of adaptive immune responses is triggered by DCs. Briefly, DCs carry 
receptors on their surface that recognize many pathogens, then engulf pathogens 
and digest them within the cell. When a DC takes up a pathogen, the cell becomes 
activated and migrates to the lymph node to present the virus antigen to 
lymphocytes.  
Adaptive immune responses act against both virus particles and virus infected 
cells via either: humoral immunity (antibodies), which mainly work via binding to 
epitopes expressed by native proteins at the surface of free virions and block viral 
attachment or penetration of target cells. Additionally, this can result in viral lysis 




dependent cellular cytotoxicity (ADCC). Alternatively, they can neutralize virus 
particles and prevent host cell entry, or by forming antibody–antigen complexes 
and stimulate macrophages (phagocytosis) or reduce the virus particles by viral 
agglutination (Figure 1.8). However, it has been found that the humoral immune 
response is not capable of protecting against progression of BK virus nephropathy, 
as patients with anti-BKV levels similar to healthy individuals still develop BKN (P. 
Comoli, Binggeli, Ginevri, & Hirsch, 2006). 
The alternative means of the adaptive immune response in controlling infection is 
a cytotoxic mechanism that works through eliminating virus infected cells; when 
the virus enters the host cell, it expresses the virus antigen on its membrane even 
before viral assembly, which means destruction of those cells is essential to avoid 
viral replication. The presented antigens are recognised and attacked either by 
cytotoxicity mechanisms mediated by CD8+ lymphocytes or humoral mechanisms 
mediated by ADCC, phagocytosis or complement activation. Even though CD8+ T 
cells and NK cells are both able to kill virus-infected cells, they utilise different 
activation and signalling mechanisms; unlike CD8+ T cells, NK cells express an 
array of activation and inhibition receptors to respond to changes caused by any 
infection. Normally, NK cell activation is inhibited by increased expression of MHC-
I molecules on target cells, that interact with NK cell inhibitory receptors and 
including killer cell immunoglobulin-like receptors (KIRs) and leukocyte 
immunoglobulin-like receptors (LILRs) (Rouse & Mueller, 2019; van Erp, van 
Kampen, van Kasteren, & de Wit, 2019). 
Finally, CD4+ T cells are key to mediating both humoral and cell-mediated 
responses against viruses, providing help for antibody production by B cells and 
the activation of CD8+ cytotoxic T cell responses targeting virus infected cells 






Figure 1.8.Humoral response  














Adaptive immune responses to BK 
1.4.2.1 Humoral immune defence  
Adaptive humoral immune responses are initiated immediately after exposure to 
BKV antigens. More than 80% of the population in early age (20-29) carry BK 
antibodies in their blood, and 71% of people aged 50-59 are seropositive for BKV 
(Adrian Egli et al., 2009). Commonly, during viral infection, the antibodies 
neutralize the virus particles by binding to the surface proteins of the virus and 
prevent it from interacting with the cell surface receptors that enable viral entry.  
In BKV infections, some virus genotypes are able to evade antibodies due to 
mutations in the virus receptors, for example, antibodies raised against type I 
viruses are not able to bind to type II viruses (Pastrana et al., 2013). Hence, we 
cannot completely rely on the recipient’s seropositivity against BK virus 
reactivation, based on a study in paediatric kidney transplants, seronegative 
recipients were at risk of BK reactivation and BKPyAN. However, being seropositive 
for BK virus does not necessarily give full protection from post–transplant 
reactivation or BKPyAN but, surprisingly, it has been observed that high levels of 
anti BK antibodies are correlated with low CD8+ responses and high levels of 
viremia. Furthermore, Leboeuf et al evaluated and compared BK virus IgG levels 
in viremic patients and non-viremic controls at different periods following 
transplantation; no significant difference was observed among the study groups 
(Leboeuf et al., 2017b). Also, in the same study, antibody levels were evaluated 
in patients who were viremic and those who cleared the virus; again no significant 
difference was detected which weakens the correlation between antibody levels 
and virus clearance and suggests that anti-BK antibodies are only a marker of past 
and recent exposure to the virus (Leboeuf et al., 2017a). However, BKV specific 
humoral immune responses play a significant role in neutralizing virus, even 
though they are unable to resolve viral latency and persistence. It is worth 
mentioning when studying BKV humoral responses there is no standard serological 
assay for measuring anti-BK antibodies. Also, sero-positivity does not necessarily 
mean the development of anti-BK T-cell memory and these factors highlight the 
importance of better understanding the mechanisms that provide specific stable 




1.4.2.2  Cellular defence 
Cellular immunity is strongly believed to play an important role in BK virus 
clearance and control of BKVN in KTR and normal individuals. Drummond and 
associates illustrated the importance of cellular immune responses in inhibiting BK 
virus reactivation in healthy volunteers (H. H. Hirsch, 2005). Further, a study 
comparing post renal transplant patients with or without viruria, and healthy 
individuals, found that KTRs had lower levels of BK specific T-cell responses in 
comparison to healthy subjects, which could be predicted due to the induction of 
immunosuppression. Moreover, a considerable amount of literature has been 
published describing links or a correlation between specific cellular immune 
responses and the control of BK virus replication; low levels of BKV-specific T-
cells, which produce INF-γ, correlate with progression to BKV nephropathy, while 
elevation of these cell populations  correlates with resolution of nephropathy (S. 
Hariharan et al., 2005; Koralnik, Du Pasquier, & Letvin, 2001; Prosser, Orentas, 
Jurgens, Cohen, & Hariharan, 2008). The global cellular immune response to BK 
virus in KTR individuals was measured using a Cylex ImmuKnow Test (Cylex, 
Columbia, MD, USA) where the mean±standard deviation of the adenosine 
triphosphate (ATP) was 102.9±58.6 ng/ml, in patients with viremia versus 
227.2±146.4 ng/ml in viruric recipients, and 231.8±150.8 ng/ml in those neither 
aviremic nor viruric. This also leads to the conclusion that a reduction in immune 
cell function is correlated with viral replication (Batal et al., 2008). 
Impaired BK-specific cellular immune responses may allow for nephropathy 
disease progression. This has led to the assumption that regular monitoring of BK 
specific T-cell responses prior to and following transplantation is considered a 
sensitive and crucial marker in identifying patients with a higher risk of 
experiencing BK reactivation. Pre-transplant and post-transplant monitoring were 
illustrated by Schachtner et al. When they compared two groups of KTR individuals 
with and without BK replication, using an INF-γ ELIspot assay to measure T-cell 
responses, they found that individuals with lower BK specific T-cell responses were 
more likely to develop virus reactivation and to have remarkable low level of INF-
γ, CD4+, CD8+ and CD3+ T-cells, whereas, recipients with a higher or more stable 
levels of specific immune cells inhibited virus replication (Schachtner, Stein, Babel, 





Many studies have aimed to identify and characterise the BK virus specific CD4+ 
and CD8+ T-cells directed against virus proteins which provide protection against 
disease reactivation. A recent report indicated that T-cell responses mounted 
against BKV are predominantly CD4 T-cells and these are able to control viral 
replication in the absence of CD8+ T-cells, in other words it is CD4 T-cell restricted 
(Schachtner et al., 2011). In 2014, Weist et al. described a mechanism behind 
CD4 T-cell recognition of BKV on antigen presenting cells; they found that the 
perforin–granzyme pathway is the mechanism behind CD4+ T-cell mediated 
killing. Additionally, CD4+ T-cells were found to up-regulate pro-inflammatory 
cytokines such as IFN-γ and TNF-α while down-regulating the expression of 
CD107a that is expressed during cytokine secretion (Weist et al., 2014) (Alter, 
Malenfant, & Altfeld, 2004). BKV-specific T-cell immunity and its role in viral 
clearance was investigated in HSCT patients; specific CD4+ and CD8+ T-cell 
recovery were associated with successful viral clearance (Apiwattanakul et al., 
2017). Additionally, KT patients with absence of BKV specific T-cell immunity pre-
transplant, tend to develop BKV DNAemia post-transplant (Schachtner et al., 
2015). 
In another context, Binggeli et al compared Tcell responses to the two main BK 
virus proteins, in healthy controls and KTR individuals with BKV viremia (Binggeli 
et al., 2007). There were lower responses to LTag compared to VP-1 Ag and it was 
also observed that VP-1 preferentially stimulated CD4+ T-cells while LTag 
stimulated CD8+ T-cells. Cellular responses to the viral LT protein were more 
frequent than responses to VP protein, plus the population of T-cells that 
specifically secreted INF-γ was remarkably higher in patient with viral clearance 
compared to controls. Surprisingly, effector memory T-cells were observed in 
patients with BKV nephropathy, indicating that BKV antigen expression can affect 
or control T-cell proliferation and expansion. In contrast, a prospective study found 
that large T-antigen specific immunity but not immunity to VP1 after 
transplantation can protect patients from development of viremia. In this regard, 
many studies have confirmed that LT Ag appears early in the virus life cycle, 
making it a target of the cellular immune response in comparison to the VP 
protein; (van Aalderen et al, 2012). To conclude, the VP protein has been shown 
to be more immunogenic and stronger than the LT protein, whilst LT is more 




VP triggered immune responses were mainly associated with reducing the viral 
load, while LT triggered responses were associated with acceleration of infected 
cell death (Blazquez-Navarro et al., 2018). 
Moreover, a number of studies have observed that BKV mediated T-cell responses 
are mediated by cytokines such as INF-γ, tumour necrosis factor (TNF), and 
granzyme B (associated with CD107 expressing T-cells) after stimulation with BKV 
VP1 and LTag proteins. Commonly, specific cellular immune responses to BK virus 
are measured by T-cell production of INF-γ and other cytokines using flow 
cytometry and multiplex analysis of PBMCs stimulated with BKV peptide mix.  
In KTR individuals the expression of cytokine expression declines as a result of the 
initiation of immunosuppression (IS) therapy aimed at reducing allograft rejection. 
Findings from Mueller and colleagues on studying post-KTR individuals with 
BKPyAN, demonstrated an expansion of T-cells showing a specific production of 
IL-2, INF-γ and TNF-α, using an ELISPOT assay and monitoring in vitro expanded 
PBMCs. The results showed responses to all BK virus capsid proteins except 
agnoprotein (large T, small t, VP1, VP2, and VP3) and interestingly these 
individuals showed greater numbers of CD4+ T-cells compared with an 
asymptomatic group (Mueller et al., 2011), whilst the T-cells that are supposed to 
produce these three cytokines were found more frequent in asymptomatic patients 
or those without virus reactivation. Mueller et al suggested that the strong T-cell 
reactivation in BKPyAN patients could be due to exhaustion of these cells and loss 
of their capacity for cytokine production (Mueller et al., 2011).  
Most T-cell studies regarding BKV infection have focused on studying in vitro PBMC 
expansion/mixed lymphocyte peptide culture (MLPC); stimulating the immune 
cells using all the five BKV antigenic peptides (15mPs) for stimulating (IFN-γ), 
which elicited CD4+ T-cell responses even though CD8+ cells are believed to be 
the core of the cytotoxic cellular response; their epitopes have been studied less 
than CD4+ T-cells, and mainly those that are restricted to HLA*0201. Now, the 
direction being taken is to be able to detect even low numbers of BKV–specific T-
cells and identification of T-cell epitopes, which are restricted to specific HLAs. In 
2016 a study utilised bioinformatics to predict 9mer epitopes in the early viral 
gene (EVGR) presented by 14 HLAs that are common in North America and 




enzyme-linked immune-spot assays, where several early studies characterized 
BKV-specific CD8 epitopes restricted to HLA A1, A2, A3, A24, B7 and B8 (Y. Chen 
et al., 2008; Cioni, Leboeuf, Comoli, Ginevri, & Hirsch, 2016; Li et al., 2006; 
Provenzano et al., 2006; Ramaswami et al., 2009; Schneidawind et al., 2010). 
Moreover, the same groups found that some BKV epitopes had significant 
homology with JCV; the same study and others suggested that previous exposure 
to JCV may lead to cross protection from BKV disease (G. R. Ambalathingal et al., 
2017). Also, a study proved the higher sensitivity of the mixed peptide pool 
method compared to the single pool. This strong level of homology raises the 
possibility of development of immune monitoring tools that may apply to both BKV 
and JCV. 
Furthermore, as mentioned, during viral infections, the immune system protects 
the host by activating innate and adaptive immune responses, including IFN 
secretion, cytolysis by NK cells as well as both specific cellular and humoral 
immunity to fight and control virus replication (Geraghty, 1987). However, most 
viruses develop strategies to evade host immune recognition and facilitate virus 
replication; one of these tactics is modulating expression of non-classical human 
leucocyte antigen (HLA) class I molecules. Several viruses were found to inhibit 
MHC molecule restricted antigen presentation to immune cells, by down regulation 
of both  major histocompatibility complex  (MHC) class-l and -ll molecules (Amiot, 
Vu, & Samson, 2014a). Other viruses modulate the expression of non-classical 
HLA class-I antigen (HLA-G) to prevent immune recognition (Shiroishi et al., 
2006). HLA-G modulation in virus infection was proposed in several virus 
infections such as Rabies, HIV-1, HSV, Epstein-Barr virus and influenza virus (H.-
X. Chen et al., 2011; Gazit et al., 2007; Lozano et al., 2002; Yan, Lin, Chen, & 
Chen, 2009) as induction of HLA-G molecules suppresses the function of several 
immune cells such as T-cells, NK-cells and antigen presenting cells (Shiroishi et 
al., 2006). Previous work in our laboratory has shown that cytomegalovirus is 
capable of inducing HLA-G expression on T cells and other leucocytes (Albayati et 
al, 2017). 
Thus, the role of immunosuppression in permitting BKV virus replication is well 
known and the focus should be directed to better understanding host immunity to 
BKV. Current approaches, after identification of remarkable numbers of BKV-




based on ethnic groups, which will be a useful monitoring tool for BKV disease 
especially for regions other than North America and Europe (G. R. Ambalathingal 
et al., 2017).  
 
1.5  Diagnosis 
Since BKVN has no current treatment, the most important approach in BKV 
disease management is to facilitate an earlier and regular viral diagnosis and 
management strategy and to intervene before progression to disease. Due to the 
lack of standardized guidelines for BKV detection, it has been suggested to initiate 
an international reference standard to improve BKV diagnosis and detection 
(Greer, Forman, & Valsamakis, 2015). A prospective study found that BKVN is one 
of the early complications following kidney transplantation and most of the cases 
appear just months post-transplant. Further, a French prospective study followed 
renal transplant recipients for 12 months; reported that BKV was detected in 
10.9% of the patients and the median time to viral load detection was 90 (23-
214) days (Almeras et al., 2011). Similar data were found in a different 
prospective study of 32 patients, (Thakur, Arora, Nada, Minz, & Joshi, 2011) which 
reported that the greatest incidence of BKV viral load was in the first month post-
transplant (Figure 1.9). Moreover, a different cohort study made the same 
findings; after 18 month of post-transplant patient follow up, they noted that the 
incidence of viruria and viremia peaked during the third month after transplant 
with 28% and 31% of patients, respectively (Koukoulaki et al., 2009). Based on 
the earlier literature, BKV screening in post-renal transplant patients within the 
first year and not after 24 months is highly recommended. Urine and plasma (PCR) 
appeared to be the most practical methods in detecting BKV in healthy people and 
BKV reactivation in post renal transplant patients. BK viruria precedes viremia by 
approximately four weeks, while that precedes BKAN and renal dysfunction by a 
median of eight weeks. However, renal biopsy and urine cytology are the main 





Figure 1.9. BK virus events in post renal transplant recipients. 
 
(Rafael Brandão Varella et al., 2014) 
 
1.5.1  Plasma 
Detecting BKV in plasma using real–time PCR is the preferred method at most 
transplant centres, due to its  high sensitivity and specificity in BKPyAN diagnosis; 
the  sensitivity reached up to 100% and specificity is approximately 90%, with a 
positive predictive value (PPV) of 50% and negative predictive value (NPV) of 
100%, even though the final viral load cut-off for BKVN has not been established 
yet but some reports have suggested that BK viral load more than 4 log copies/ml 
is significantly associated with BKVN on biopsy (H. H. Hirsch et al., 2005); (Ding 
et al., 2002; H. H. Hirsch et al., 2002; H. H. Hirsch & Steiger, 2003). 
1.5.2  Urine 
Urine analysis is considered the most common non-invasive method of BKV 
detection. It can be screened for cytology (decoy dells): cells with enlarged 
nucleus containing a single large basophilic intra-nuclear inclusion. Or quantitative 
estimation of BKV DNA using real time-PCR assays which are superior to cytology 
regarding sensitivity and specificity. When comparing the two techniques, urine 
PCR has 100% sensitivity and 78% specificity compared to 25% sensitivity and a 
specificity of 84% through visualising decoy cells. Thus, urine viral load 
assessment in BKV screening is an essential and conventional tool in detection of 




with viral loads more than 107/ml is considered a risk factor for BKVN, even though 
the urine test only provides information limited to the presence of the virus DNA 
in the urothelium tissue. 
Other types of urine analysis have been proposed, such as: detecting BKV VP1 
mRNA levels as a way of measuring viral replication (Ding et al., 2002); and 
measuring BKV aggregates in urine and the Haufen method that is used to 
describe cast–like three dimensional BKV aggregates. However, all these 
approaches either need further validation or are expensive or not suitable for 
routine lab testing as they require electron microscopy (Singh et al., 2009)  
Ambalathingal et al., 2017). 
1.5.3  Biopsy 
Renal biopsies are still the gold standard in diagnosis and confirmation of BKVN, 
especially for patients with high viral load more than 4 log10 copies/ml, to exclude 
other renal underlying diseases and drug toxicity. Multiple biopsies from medulla 
tissue should be performed as the virus is not present uniformly within the tissue 
and to avoid sampling error. 
Electron microscopy (EM) of allograft biopsies is considered one the best definitive 
tools in diagnosis and confirmation of BKPyAN. It is preferred over histology as it 
not only aids differentiation between acute rejection and BKVN, but also provides 
for a differential diagnosis of other viral infections within allografts such as 
adenovirus, Herpes Simplex virus, Epstein–Barr virus and CMV. EM is able to 
measure the dimension of the viral inclusions, which are typically between 30-50 
nm in diameter and appears as crystalloid structures, whereas the herpes family 
and adenovirus inclusions are remarkably bigger; about 120-150 nm and 70-90 
nm, respectively (Bardak et al., 2016). But as mentioned before electron 
microscopy is not suitable for routine labs.  
Histologically, BKV disease has been classified into three grades to allow for a 
comparative analysis. Tubular atrophy and interstitial fibrosis are considered the 
most crucial signs of poor outcome and signs for immediate reduction of 
immunosuppression therapy (Masutani et al., 2012; Sar et al., 2011; R. Sharma 





1.6  Factors influencing BKV reactivation after kidney 
transplant  
It is well known that the main factor affecting BKV reactivation and progression of 
BKPyAN in renal transplant recipients is immunosuppressive therapy (H. Hirsch, 
Yakhontova, Lu, & Manzetti, 2016; H. H. Hirsch, Drachenberg, Steiger, & Ramos, 
2006; H. H. Hirsch & Steiger, 2003), in addition to active tubular lesions from 
surgical trauma which could increase the possibility of BK virus reactivation. 
Briefly, KTR individuals receive two types of immunosuppressive drugs: induction 
medication that is administered immediately after the transplant to prevent the 
acute rejection risk, such as monoclonal or polyclonal antibodies that attack host 
immune cells (thymoglobulin/ATG) or attack CD25-expressing cells (anti-CD25), 
and maintenance therapy, such as cyclosporine and corticosteroids that block T 
cell communication. These are in addition tacrolimus that reduce immune 
responses to the transplanted organ. Hirsch et al observed a strong association 
between tacrolimus administration and risk of developing BK viremia when 
compared with cyclosporine (Hirsch & Randhawa, 2013). Also, there is a 
correlation between risk of developing BK viremia and corticosteroid 
administration. A combination of three different suppressant agents also appears 
to associate with greater risk of BK reactivation (Borni-Duval et al., 2013). But 
the risk of BK viremia appears to be less common in people who are receiving 
mTOR inhibitors (sirolimus or everolimus), maybe because they are considered 
less potent than the calcineurin inhibitors (Jacobi et al., 2013; Suwelack, Malyar, 
Koch, Sester, & Sommerer, 2012). 
Apart from immunosuppressive drugs, many other factors are believed to 
influence BKV disease. Shenagari et al, claimed that the most predictive factor for 
developing BK viruria in post-transplant recipients is undergoing pre-transplant 
dialysis treatment. Additionally, donor and recipient sero-status can play a role in 
development of BKVAN. When the donor has anti-BK antibodies and the recipient 
is seronegative that may increase the risk of developing BK viremia and even 
acute rejection when compared to seronegative donors and recipients, presumably 
because the recipient is BKV negative and hence has no memory cells or antibodies 
specific for BKV (Shenagari et al., 2017). Furthermore, the difference in anti-BK 
titre between the donors and the recipients may be a risk for reactivation 




suggested to be associated with virus reactivation, in addition to higher level of 
HLA mismatch, ischemic injury, prior graft loss and prior acute rejection (D. L. 
Bohl et al., 2008; D. L. Bohl et al., 2005; H. H. Hirsch et al., 2002); (Leboeuf et 






Table 1.1. Factors that influence BKV disease. 





Virus related  Donor related  Recipient related  
Virus genotype  Mechanical or ischaemic    
reperfusion injury 
Low or absent cytotoxic T 
lymphocytes 
Mutation in non- 
coding control 
region  
Kidney from deceased donor 
absence of HLA-C7 
Male 
 BKV seropositive donor Elderly people 
 High BK- specific antibody titres 
(marking of higher recent BKV 
exposure and possibly graft load) 
White and Asian ethnicity 
 Older age (defined as older than 60 
years) 
Cytomegalovirus infection 
 Female Delayed graft function 
 African American ethnicity Diabetes mellitus 
  Post –transplant early BKV 
reactivation of donor 
origin 
  BKV seronegative 
  ABO-mismatch 
  Human lymphocyte 
antigen mismatch 
including absence of 
matching HLA-B 44 and 
HLA- DR15 
  Steroid maintenance 
  Lymphocyte depleting 
agents 
  Immunosuppressive 
therapy 




1.7 Management and intervention 
Currently, the keystone strategy in preventing BK reactivation would be early and 
regular monitoring of BKV replication combined with reducing, stopping or 
modifying the immunosuppressive therapy regimen with care to avoid immune 
restoration and rejection. Unfortunately, there are only a few controlled trials in 
the management of BK viremia and BKVN (Brennan et al., 2005; Johnston et al., 
2010).   
The recommended approach in controlling BKV infection in renal transplantation 
is the gradual reduction of immunosuppression, which comes with the risk of acute 
rejection. According to the Kidney Disease Improving Global Outcomes (KDIGO) 
recommendations, transplant recipients should be screened monthly for the first 
three to six months after transplant, then every three months for the first year of 
the recovery. Unless there is unexplained increases in serum creatinine levels after 
resolving of acute rejection, then the test should be performed more frequently 
(Lamarche et al., 2016); (Figure 1.10). As mentioned earlier, the most useful 
screening tool for BK viremia or viruria is quantification of virus DNA using real 
time-PCR assays. Additionally, renal biopsies should be performed if the viral load 
exceeds 10,000 copies/ml, to track any histological changes that are associated 
with BKPyAN.   
A study suggested that fluctuations in the immunosuppressant levels correlated 
with co-existence of BKVN and acute rejection, indicating more clinical care and 
monitoring during drug administration, particularly for patients showing either 
acute rejection or BKVN and particularly both (van Aalderen, Heutinck, Huisman, 
& ten Berge, 2012). Even though there are no perfect approaches in reducing 
immunosuppression, many approaches have been suggested. It has been shown 
that administration of Calcineurin inhibitor (CNI) based therapies are not 
associated with BK viremia after transplant, whereas it is known to be one of the 
major risks of developing BKVAN and nephrotoxicity (Alméras et al., 2008; Matas, 
2011). 
There is no strong evidence of any antiviral drugs with clinical efficacy against 
BKV, even though many studies demonstrated the anti-BKV effect of agents such 
as leflunomide, cidofovir, fluoroquinolones and cyclosporine, in treating BKVN. In 




effects with decreases in immunosuppression. But most of the cases have come 
from uncontrolled observational studies, which makes it difficult to consider 
therapeutic efficacy (Burgos et al., 2006; Josephson et al., 2006; Song et al., 
2016; Wadei et al., 2006).  
 
Figure 1.10. Clinical algorithm for screening BKV reactivation 










1.7.1  Intravenous immunoglobulin (IVIG) 
This is one of the proposed options in treating BKV nephropathy. As in other viral 
infections, immunoglobulin contains antibodies that neutralize the virus particles 
and prevent host cell entry. Based on in vitro incubation of BKV with IVIG for two 
hours before infection, 90% of the viral DNA was diminished whilst, if the IVIG 
was given directly to cells before the 2 hours, the percentage was significantly 
less. In contrast, a different study observed no benefit and even worsened long 
term effects because of the high dose of IVIG (Halim et al., 2016). Many case 
reports and case series studies have demonstrated the effect of IVIG in BKV 
control, but no control studies have been reported (Sener et al., 2006; Wadei et 
al., 2006) (Almeras et al., 2011). 
1.7.2  Fluoroquinolone 
In vitro, Fluoroquinolone administration was proposed as a potential agent in 
controlling BKV reactivation. It inhibits LT antigen helicase activity and reduces LT 
antigen expression (M. C. Sharma et al., 2006). Based on a trial when 
Fluoroquinolone was administered as antibiotic prophylaxis during the kidney 
transplant only a few of the patients who received Fluoroquinolone developed 
viremia (Wojciechowski et al., 2012). However, after three months of treatment 
in KTR individuals it failed to reduce the viral load and prevent viremia and caused 
bacterial resistance.   
1.7.3  Adoptive immunotherapy 
Cellular immune therapy refers to ex-vivo transfer of BK-reactive T-cells 
(educated) in order to restore antiviral immunity in immunocompromised 
individuals. The approach has been proved to be effective and safe in treating or 
preventing BK virus reactivation. It was developed in the early 1990s by Riddell 
to treat a patient suffering from Epstein Barr virus (EBV) complications following 
a haematopoietic stem cell transplant (Riddell & Greenberg, 1990); (Mani, Jin, & 
Schmitt, 2014). Over the past decades, many chronic virus–associated diseases 
have been treated using T-cell adaptive transfer, such as with CMV. In 2017, 
Tzannous et al used adoptively transferred virus-specific T cells from third party 
donors that recognize five common viruses: BKV, EBV, CMV, and HHV-6 and 
adenovirus in 38 patients. The aim was to evaluate cure rates for patients and 
where clinical improvement was demonstrated in 92% of patient treated for BKV 




replication and BKPyVN found that adoptive T- cell immunotherapy may influence 
BKV replication and reduce virus load (Jahan et al.). Furthermore, identifying 
immunodominant peptides would be another interesting immunotherapeutic 
approach for treating transplant recipients. The characterization of viral 
immunogenic antigens or T-cell immunodominant epitopes is essential for the 
successful generation of virus–specific T-cells and peptides for vaccination. 
Several research groups have successfully defined persistent virus epitopes via in 
vitro expansion of virus specific T cells, using synthetic viral peptides, however, 
there are only very limited studies regarding BKV immuno-dominant epitopes. In 
2003, Comoli and his group were the first who produced BK-specific T-cell lines 
from renal transplant patients with viremia; they were able to produce active T-
cells against BK infected cells in vitro (P. Comoli et al., 2003).  Furthermore, a 
different group succeeded in producing 15 lines of BK specific T-cells, but the cell 
expansion was limited and 20% of NK cells was found in the final product (Blyth 
et al., 2011). Clinically, an experiment where 11 HSCT recipients were treated 
with either single or multiple viral infections with a donor derived multivirus 
(Epstein-Barr virus, adenovirus, cytomegalovirus, BK virus, and human 
herpesvirus 6) specific T-cell line. Five of seven patients were completely cleared 
from BKV viremia without any significant side effects; in addition, a role for the 
PD1/PDL1-L2 receptor on BKV infected cells was proposed in controlling viral 
reactivation as when expressed by virus infected cells, prevening T-cell activation 
and inhibition of the receptors which results in restoration of T-cells and their 
expansion (Dekeyser, Francois, Beaudreuil, & Durrbach, 2015). Recently, a clinical 
trial succeeded in treating 86% solid organ and stem cell transplant recipients with 
BKV viremia using virus  specific cells that were isolated from donors and/or 
unrelated donor (third party) blood (Nelson et al., 2020). Even though 
immunotherapy solutions in management of BKV disease are still in the early 
stages of development cellular immunotherapy should be considered at least for 








1.8 Thesis outlines  
The aim of the thesis is to gain more understanding of the humoral and cellular 
immune responses to BKV in healthy subjects and in transplant recipients. 
Additionally, to gain better insights of pre-transplant and post-transplant risk 
factors for BKV infection, including pre-transplant anti BKV levels and virus 
genotypes involved. 
So, in the first place we hypothesized that the presence of BKV specific cellular 
immunity pre-transplant may influence the severity of the infection post-
transplant. Secondly, we investigated whether BKV infection will increase HLA-G 
expression that promotes viral evasion. Further, we tested the hypothesis that 
BKV sero-reactivity is correlated with preceding viremia and risk of BKV infection 
in patients positive for some HLA alleles. Finally, we tested if some particular BKV 
genotypes were associated with deployment of BKV viremia and progression of 
disease. 
The current study was conducted to primarily evaluate the following aspects:  
• investigate cellular immune responses in renal transplant recipients with 
different virus replication status, to overlapping 15 mer peptide pools 
representing all virus antigens, specifically, interferon γ secreting cells, 
and comparing to healthy controls, despite the low pathological potential.  
• Measure immunoglobulin G responses to BKV VP1 antigen using an ELISA 
assay to evaluate the presence of specific immunity and identify previous 
infection in renal transplant recipients. 
• Measure cell surface HLA-G in healthy and renal transplant recipients to 
explore its importance in viral evasion of immunity  
• Measure soluble plasma HLA-G (sHLA-G) in healthy and renal transplant 
receipts. 
• Evaluate BKV IgG antibody quantitatively using a standard ELISA with 
recombinant antigen and not cross reacting with other polyomaviruses  
• Study the association between the recipients’ HLA allele status and 
development of BKV viremia. 




• Investigate the prevalence of BKV genotypes in renal transplant recipients 
and study the association of particular genotypes to the development of 















   
2 Materials and methods  
2.1  Study population and sampling 
2.1.1  Healthy subjects 
Healthy volunteers from the Institute of Infection and Global Health, Ronald Ross 
Building, University of Liverpool, were recruited through an advertisement in the 
department monthly magazine. They were identified as healthy subjects and were 
recruited to donate urine and later blood samples after signing a written informed 
consent. Project ethical approval was granted by the Interventional Ethics 
Committee (Ref: UoL001481). 71 urine samples were collected in 20 ml sterile 
containers and stored at -20ºC until the time of the experiment. Subsequently, 
blood samples were collected from each urine positive donor under aseptic 
conditions in 10 ml heparin vials and then processed using density gradient 
separation for PBMC isolation. DNA was extracted from the urine samples and 
separated plasma was stored at -20ºC. 
2.1.2 Renal transplant patients 
From mid-2018 kidney transplant recipients (KTR) from the Royal Liverpool and 
Broadgreen University Hospital were recruited and divided into four different 
groups as follows: a) BKV negative, never qPCR positive (12 patients), b) BKV 
positive, currently plasma qPCR positive (8 patients), c) historically BKV positive 
patients who are currently negative but were plasma qPCR positive in the past (13 
patients), and d) pre- transplant (2 patients). All patients were treated with 
standard immunosuppressive therapy and consented to donate 10-40ml of blood 
and 20ml of urine, collected by Hospital research nurses. The specimens were 
transferred to the lab for DNA extraction, PBMC and plasma isolation. Urine and 
plasma samples were stored at -20ºC. Ethical approval was obtained from Central 
Bristol NRES committee (ID: IRAS 229214; PR 17/SW/0220).  
Furthermore, pre-transplant samples, comprising archived frozen serum samples, 
were collected from the Royal Liverpool University Hospital Virology Laboratory. 
Four different samples were used from each KTR: pre-transplant, pre-viremia, 






Figure 2.1. Sampling and methods used in chapter 3 
 Measuring Cellular immune responses to BKV in healthy individuals and KTRs, urine and blood samples were collected and 






Figure 2.2.sampling and methods used in chapter 4 
 Blood samples were used to investigate Human Leucocyte Antigen – G (HLA-G) expression in BKV infected individuals using 
flow cytometry.  
 
Figure 2.3. Sampling and methods used in chapter 5 
 Levels of anti BKV IgG in KTRs were studied by collecting three different urine samples from patients: pre-viremia, viremia 







Figure 2.4. Methods used in chapter 6 
To identify BKV genotypes among KTRs with BKV viremia; urine samples were collected from patients with BKV viremia, then 
nested PCR and Sanger sequencing were performed. Later, the obtained sequences were retrieved and compared between 
the samples  
 















2.2  Stocks and reagent preparation 
All chemicals and reagents used were obtained from either Sigma Aldrich, UK or 
Thermo Fisher, UK, while most laboratory disposables, tips and plastic ware were 
purchased from Starlab, UK unless otherwise stated. 
1X PBS 
Two and a half PBS tablets were dissolved in 500 mL distilled water, autoclaved 
(for sterile work) and stored at room temperature before use. 
Tissue culture medium 
RPMI 1640 Medium containing L-glutamine by Life Technologies Ltd., UK, was 
treated with 10% (v/v) FBS and 100U penicillin / 0.1 mg/ml streptomycin (both 
from Sigma, UK) stored at 4˚C.  
3 M Sodium acetate (CH3COONa) solution, pH 5.2 
24.6 g of sodium acetate powder was completely dissolved in 70 mL of distilled 
water, then the solution topped up with glacial acetic acid to the required pH, 
filtered and stored at RT. 
FACS buffer 
FACS buffer was prepared by making up 1X PBS to 0.5% (v/v) FBS, 2 mM EDTA 
prepared freshly every time. 
TAE buffer x1 
The tris base was dissolved in 750 ml of deionized water, then acetic acid, EDTA 
and water were added to adjust the volume to 1 L. Then the stock solution was 
diluted 1:10 before use. 
CFSE stain 
To prepare a 5 mM stock of CFSE stain (Invitrogen C34554); 18 µl of DMSO was 




Eppendorf tube and stored at -20˚C̊. On the day of the experiment, the CFSE 




2.3  Cellular assays 
2.3.1  PBMC separation 
Fresh blood (35-40 ml) was collected from donors in heparin tubes (green). First, 
all the separation process was undertaken in a biosafety cabinet II (MAT-2 CLASS 
II, Thermo Fisher Scientific Inc. USA). The cabinet was cleaned with 70% ethanol, 
then the samples were aliquoted into two 50 ml sterile Falcon tubes (Fisher 
Scientific Inc. USA). 1/2 volume of Ficoll-Paque Plus solution (Sigma-Aldrich Ltd, 
UK) was added then the blood sample was pipetted carefully over it, using an 
automated pipette without disturbing the Ficoll layer. The Falcon tube was then 
covered and balanced then placed in the centrifuge (Sorvall, Thermo Fisher 
Scientific Inc., USA) for 25-30 min at 400 g with brake off and 1 Acceleration 
setting at 22˚C. Following the previous step, the tube containing the sample was 
removed from the centrifuge carefully using a rack to avoid disturbance of the 
layers, buffy coat and plasma were transferred by pipette, each to a new 15 ml 
sterile tube. Then, the cells were washed twice by filling the tube with sterile PBS 
and centrifuged for 5 min at 400 g with acceleration setting 5 and brake 5 at 22˚C, 
then the pellet was re-suspended between the two washes. After the second wash, 
cells were re-suspended in complete warm RPMI 1640 medium plus 2 mM L-
glutamine (with 10% FBS and 1% Penicillin-Streptomycin), then counted and 
adjusted to reach the required volume for both surface labelling and ELISPOT 
experiments. 
 
2.3.2 Preparation of BK Virus peptides 
A peptide pool of 170 peptides (15 amino acids in length with overlaps of 11 amino 
acids chemically synthesized, analysed and purified by LC-MS) of BKV early large 
T antigen, small-T antigen, VP1, and VP2 were purchased from JPT Peptide 




(Sigma-Aldrich Inc., UK), diluted with PBS to create stock solutions (25 mg/ml). 
The peptide stocks were aliquoted and stored at -20̊ C. 
 
2.3.3   Enzyme-linked immune-spot assay (ELISPOT)  
This test is known to be one of the fastest growing and most sensitive tools in 
biomedical research for studying cytokine secretion at the single–cell level, in 
addition to its crucial role in vaccine development, transplantation studies, virus 
research (such as HIV-1), cancer research and allergy research. 
In this assay, the cells were cultured on a pre-coated surface with a specific 
capture antibody, in the presence or absence of stimuli. Then cell-secreted 
proteins in response to the stimuli such as cytokines were captured by the specific 
antibodies on the coated surface. After incubation for an appropriate period, cells 
were washed, and the detection antibody was added to the wells containing 
secreted cytokines. These detection antibodies were either biotinylated and 
followed by a streptavidin-enzyme conjugate, or the antibody was directly 
conjugated to an enzyme. Lastly, the precipitating substrate was added to develop 
visible spots on the wells. Each spot corresponds to an individual cytokine-
secreting cell. 
Procedure 
In this study INF-γ secreting cells were evaluated, using a Human IFN-γ ELISpot 
PLUS (ALP) kit from Mabtech AB (Sweden), following the procedure given: 
A-Preparation of the ELISPOT plate: 
1- Wash the required number of strips with 200 µl/well sterile PBS. And keep 
the unused strips in the provided foil. 
2- Then, condition the plate with 200 µl/well complete RPMI 1640 plus 2 mM 
L-glutamine media (with 10% FBS and 1% Penicillin-Streptomycin), for 30 
min at RT. 
B-Incubation of the cells in the plate (sterile conditions): 
1-Discard the medium and add the stimuli followed by 100 µl of cell 
suspension. Alternatively, mix the cell suspension with stimuli in separate 




2-Use the mAb CD3-2 as positive control at dilution of 1:1000. 
3- Cover and incubate the plate in a 37ºC humidified incubator with 5% CO2 for 
24-48 hours without moving the plate. 
4- Wrap the plate with aluminium foil to avoid evaporation. 
C-Detection of the spots: 
1- Discard the cell suspension and wash the wells four times with PBS 200 
µl/well and dry the plate against a blue paper towel. 
2- Dilute the detection antibody to 1 µg/ml in PBS. Then Add 100 µl/well of 
the diluted detection Ab and incubate it for 2 hours at RT. 
3- Wash the plate four times and dry it well against a blue paper towel. 
4-  Add 100 µl/well of streptavidin (ALP) after 1:1000 dilution and incubate for 
1 hour at RT. 
5- Wash the plate four times with PBS. 
6- Filter the ready to use substrate using a 0.45 µm filter, then add 100 
µl/well; the spots should appear within 5-20 min. 
7- Stop colour development by washing the plate with distilled or tap water, 
leave it to dry then count the spots using an ELISPOT reader (Autoimmun 
Diagnostika GmbH, Germany).   
 
2.3.4  HLA-G expression 
PBMC culture with BKV peptides  
A 48 well plate was designed for culture of PBMC with the BKV peptide pool, 
divided into three parts: three days, five days and seven days. Each part was 
divided into two other parts; stimulated with 1 µg/ml peptide mix and non-
stimulated control wells. Then the plate was incubated at 37ºC with 5% CO2 until 
the time of acquisition. 
2.3.4.1 Surface staining and labelling 
After incubation, cells were mixed by pipette and 300 µL was aspirated into several 




2.3.4.2 Antibody labelling 
The freshly extracted PBMCs from healthy donor were cultured with the BKV 
peptide pool and then labelled with monoclonal antibodies (mAbs) for each antigen 
expressed by different subset of T lymphocytes. The selected Abs were based on 
optimal matching of three colours (FITC, PE, and APC) that are suitable for the BD 
FACSCANTO II flow cytometer machine (BD Biosciences, Oxford).  
2.3.4.3 Flow cytometry 
The assay is based on labelling cell cultures with fluorescent Abs tagged with 
fluorochromes that emit light of a defined wavelength when exposed to a special 
laser with known wavelength. Inside the machine, many detectors are employed 
to determine scatter patterns of labelled cells; these are converted into forward 
(FSC) and side scatter (SSC). FSC is for determining cell size whereas SSC 
depends on the cell’s granularity, which leads to the ability to differentiate 
different cell populations in some circumstances. 
Procedure 
1. Aliquot 300 µl of fresh or cultured PBMCs in all your tubes  
2. Dispense 3 µl of anti-human HLA-G APC Monoclonal antibody (MEM-G/9; 
Thermo Fisher Scientific Inc., USA) in tubes except negative control and 
isotype control. 
3. Add 3 µl of anti-human CD3 FITC (Bio Legend Inc. USA) to the required 
tubes. 
4. Load 3 µl of anti-human CD4 PE, anti-human-CD8 PE, anti-human CD56 PE, 
anti-human-CD14 PE and anti-human-CD19 PE (all from Bio Legend Inc., 
USA) into the correspond tubes (Table 2.1). 
5. Aliquot 3 µl of mouse IgG1 Isotype control APC (Thermo Fisher Scientific Inc. 
USA) in isotype labelled tube. 
6. Vortex and incubate at 4ºC for 30 min or at RT for 20 min in the dark. 
7. After the incubation, fill the tubes with 2 ml of PBS and spin at 400 g for 8 









Table 2.1 Monoclonal Ab used for HLA-G phenotyping. 
Cell type  Antibodies Label Company  Host  volume 
T-helper Anti-CD3+, CD4+, HLA-G FITC+PE+APC BD Mouse 3µl 
T-cytotoxic Anti-CD3+, CD8+, HLA-G FITC+PE+APC BD Mouse 3µl 
NK cells Anti-CD3+, CD56+, HLA-G FITC+PE+APC BD Mouse 3µl 
Monocytes  Anit-CD14+, HLA-DR+, HLA-G FITC+PE+APC BD Mouse 3µl 
B cells  Anti-CD19+, HLA-G PE+APC BD Mouse 3µl 
Isotype  Mouse IgG1 APC BD Mouse 3µl 
Negative 
control 
- -    
 
Cells were assessed using a BD FACS CANTO II flow cytometer. Later, samples 
were analysed with Flow JO software provided by (FlowJo, BD LLC. USA), cells 
were gated for lymphocytes and monocytes, then each gate was moved to a new 
graph with a scale of cell labels to define each type of cell. 
 
2.4  BKV ELISA 
Both healthy subjects and patient participants were tested for anti BKV-IgG. A 
semi-quantitative Sandwich enzyme-linked immunosorbent assay (ELISA) 





Stored plasma samples were thawed at RT for 30 min before the experiment, then 
centrifuged for 5 s at maximum speed and transferred to the assay well within 15 
min. 
 
  Procedure 
 
1. serum samples were Diluted 101 times in dilution buffer (eg: 5 µl of serum 
to 500 µl of dilution buffer, each sample in duplicates. 
2. Then,100 µl of standards and diluted samples incubate for 30 min at RT. 
3. After incubation, wash the wells four times with 250 µl of wash buffer. 
4. Mix the bottle of anti-IgG conjugate and add 100 µl into each well, then 
incubate for 30 min at room temperature.  
5. wash again as step 3 
6. Pipette 100 µl of TMB-O substrate into each well and incubate for 10 min at 
RT in the dark. 
7. Stop the reaction by adding 100 µl of stop solution. 
8. Measure the absorption at 450 nm with microplate reader within 10 min of 
adding the stop solution. 
 
 
2.5  Soluble HLA-G ELISA 
Plasma samples from healthy subjects and post KTR individuals from Liverpool 
Royal Hospital with or without detected BKV DNA, were tested for s HLA-G by 
Sandwich ELISA. The commercial kit was provided by Exbio (Prague, Czech 
Republic) and was used for quantitative measurement of s HLA-G. Briefly, the 
principle of the test is that calibrators and samples were incubated in a pre-
coated well with anti sHLA-G antibodies for 20 hours. Then the wells were 
washed, labelled with monoclonal anti-human β2-microglobulin, and incubated 
for 60 min. Following another wash, substrate solution (TMB) was added to 
react with the remaining conjugate. Finally, the reaction was terminated by 
adding acidic solution to stop the reaction and measure the absorbance. The 




All the reagents were brought to RT 30 min before the experiment. 
Sample preparation 
Stored frozen (-20ºC) EDTA plasma samples were thawed just prior to the 
assay. Subsequently, the samples were diluted eight times in dilution buffer 1 
provided and mixed well. 
Reagent preparation 
S HLA-G lyophilized master calibrator was reconstituted in 700µl of distilled 
water, left to dissolve for at least 15 min at RT to obtain a stock solution of 
625 units/ml concentration. Then, five serial 2-fold dilutions were performed 
from the stock. Working conjugate solution was prepared of one part of 
concentrate conjugate solution and 99 parts of conjugate diluent. Then, wash 
concentrate solution was prepared by diluting one part of the concentrate wash 
solution and 9 parts of distilled water. 
Assay procedure 
1-Add 100 µl of calibrators, diluted samples and dilution buffer into the 
microtiter plate wells. 
2- Seal the plate and incubate at 2-8ºC for a maximum of 20 hours without 
shaking. 
3-Wash the wells five time with the diluted wash solution.  
4-Dispense 100 µl of conjugate working solution into each well. 
5- Incubate the plate for 1 hour at RT, then place it on an orbital shaker at 300 
rpm. 
6- Wash the wells 5 times with the diluted wash solution.  
7-Pipette 100 µl of substrate solution and cover the plate with aluminium foil 
to avoid light exposure. 
8-Incubate the plate for 25-30 min at RT without shaking. 
9-Stop the reaction by adding 100 µl of stop solution. 
10-Read the absorbance of the plate by microplate reader at 450 nm within 5 







2.6  Molecular assays 
 
2.6.1  DNA extraction 
Viral nucleic acid was extracted using a QIAamp DSP Virus Kit (Qiagen Inc, 
Germany). The tubes have a QIAamp silica-based membrane, this membrane 
binds to the nucleic acids from lysed samples, while the rest of the lysate is rapidly 
removed by vacuum pressure. Then, the bound nucleic acids in the membrane are 
washed to remove contaminants and then eluted in a volume of 20 µl or 60 µl. 
Sample and Reagent preparation 
Preparing Protease enzyme solution: 
The entire contents of the vial containing 4.4 ml Protease Solvent was added to 
the lyophilized Protease vial and mixed carefully by inverting the vial several 
times, to avoid foaming. 
Lysis Buffer Preparation: 
Lysis buffer was prepared by adding carrier RNA to an internal control; the purpose 
of this mixture was to improve viral DNA binding to the column membrane. Carrier 
RNA solution was prepared by adding 310 µl of Elution Buffer (AVE) to a tube of 
310 µg lyophilized carrier RNA to obtain a solution of 1 µg/µl. Then, the volume 
of Lysis Buffer -carrier RNA mix needed per sample was calculated.by selecting 
the number of samples to be processed and provided lysis buffer volume and apply 
it to the following equation: n x 0.55 ml = y ml  
y ml x 11.2 µl/ml = z µl  
Where: n = number of samples to be processed y = lysis buffer volume, z = carrier 
RNA/elution buffer (AVE) volume to add to lysis buffer. 




Using a measuring cylinder, 25 ml of ethanol (96–100%) was added to the 19 ml 
concentrated Wash Buffer 1 (AW1) bottle and mixed well before use. 
Wash Buffer 2 (AW2) preparation 
30 ml of ethanol (96–100%) was added to 13 ml concentrated Wash Buffer 2 
(AW2) bottle and mixed well before the procedure. 
 
Procedure: 
1. Add 75 µl of the Protease solution into each lysis tube.  
2. Pipette 500 µl plasma or serum to the lysis tube. Then Add 500 µl of prepared 
lysis buffer (containing 11.2 µg/ml carrier RNA). 
3. Incubate at 56°C in a heating plate for 15 min. 
4. Centrifuge at full speed for ≥5 s  
5. Open the tube with care.  
6. Pipette 600 µl ethanol (96–100%) into the lysis tube, c, Incubate for 5 min at 
RT (15–25°C). 
7. Centrifuge at full speed for ≥5 s.  
8. Carefully load all the lysate into the Column Extender without touching the 
column tube membrane or wetting the rim. 
9. Turn on the vacuum pump to draw in all the lysate, then open the valve and 
release the vacuum pressure.  
10. Pipette 600 µl wash buffer 1 to the column tube. 
11. Load 750 µl wash buffer 2 to the column tube without wetting the rim 
12. Carefully without wetting the rim add 750 µl of ice cooled ethanol (96–100%) 
to the column tube.  
13. Insert the column tube into a new dry wash tube, and centrifuge for 1 min at 




14. Place the column tube in a new wash tube and incubate for 3 min at 56°C with 
open lid to dry out any moisture. 
17. pipette 20 µl to 60 µl of Elution Buffer onto the centre of the membrane.  
18. Secure the lid and incubate for ≥3 min at room temperature (15–25°C).  
19. After the incubation, spin for 1 min at full speed (approximately 20,000 x g, 
or 14,000 rpm),  
 
 
2.6.2  Nucleic acid amplification (QPCR) 
DNA amplification and quantitation were performed by quantitative real time PCR 
using artus BK Virus PCR Kits CE (Qiagen). The kit was designed for ready to use 
of BKV detection system by DNA amplification on Rotor-Gene instrument. The kits 
provide reagents; master mix and primers were designed for specific amplification 
of a 274 bp region of the BK virus genome.   
 
Procedure: 
1. Prepare and place the required number of PCR tubes in the cooling block. 
2. Prepare the master-mix according to the following (per sample): The reaction 
mix typically contains all the components needed for PCR except the sample. 
3. Add 10 µl of the prepared master mix into each of the PCR tubes. Then add 15 
µl of the sample DNA to the mixture.  
4. Add 15 µl of each of the four quantification standards, as a positive control and 
15 µl of water as a negative control. 
5. Close and insert the tubes into the Rotor-Gene instrument and secure it using 
the security ring.  
6. Create the following temperature profile:  
45 three step cycles: 15 s at 95ºC, 30 s at 65ºC and 20 s at 72ºC. 





Table 2.2. QPCR master mix preparation. 
BK Virus RG Master 7 µl 
BK Virus RG Mg-Sol 3 µl 
BK Virus RG IC 1.5 µl 
Total volume 11.5 µl 
 
 
2.6.3  BKV genotyping 
After identifying BKV positive donors, their samples were genotyped to identify 
and estimate the prevalence of BKV genotypes in post kidney transplant 
recipients. The genotyping  protocol was designed based on amplification of a 100-
bp region of theVP1 gene of BKV as described in (Morel et al., 2017); the primers 
were designed for nested PCR by (OligoPerfect™ Designer, Thermo Fisher 
Scientific Inc. Web Tools): 
F (5`-GGTYATTGGAATAACTAGYATGC) and  
R (5`-TCCAARTAGGCCTTATGRTCAG). The same method used previously for DNA 
extraction was applied. 
 
2.6.3.1 Nested PCR 
Primers: 
Primer design and preparation 
The outer primer for the first PCR was frwBKVP1 
(5′CCCCAACCAAAAGAAAAGGAGAGTGTCAC3′) and revBKVP1 (5′ 
GTCTTTCTGTGCCCCATCAAACACCCTA3′) and 2 frwBKVP1in2 
(5′GGAGGAGTAGAAGTTCTAGAAGTTAAAACT3′) and 2 revBKVP1in2 (5- 
GGAAATTGGGTAAGGATTCTTTACAGATCT3′). The inner primer  sequences were 
obtained from (Morel et al., 2017) and designed in SIGMA while the outer pair 




as lyophilized powder that were prepared based on the technical sheet. The 
amplification master mix was prepared based on the protocol given in Table 2.2. 
Table 2.3 BKV genotyping (PCR mix preparation). 
 




(°C) Time Cycles 
Initial Denaturation 95 04:00 




Annealing 55 00:20 45 cycles 
Elongation 72 01:00 
  Elongation 72 10:00 
 




(°C) Time Cycles 
Initial Denaturation 95 02:00 




Annealing 55 00:30 35 cycles 
Elongation 72 01:00 
  Elongation 72 10:00 
 






qPCR Buffer w/o 
MgCl2 (from kit: 
10966034) 
10 X Invitrogen 
5 
1.0 X 40 
MgCl2 (from kit: 
10966034) 
50 mM Invitrogen 
1.5 
1.5 mM 12 
Molecular Grade H2O  / / Invitrogen 35.3 / / 282.4 
dNTP (18427088) 10 mM Invitrogen 1 0.2 mM 8 
Taq (10966034) / / Invitrogen 0.2 2 U/rxn 1.6 
Forward primer:  10000 nM IDT 1 200 nM 8 
Reverse primer:  10000 nM IDT 1 200 nM 8 





DNA Input: 5.0 40 





2.6.3.2 Gel visualization 
60 ml of TBE buffer was added to 1.2 g of 2% agarose powder gel, mixed well, 
heated in a microwave for 2.5 min and allowed to cool down. Then 6 µl of SYBR 
safe gel stain was added to the gel, mixed and poured into the gel chamber and 
left to solidify. The gel tank was filled with 1x TBE buffer. 7 µl of sample, negative 
control and appropriate electrophoresis ladder were added to the wells. Finally, 
the gel was run for 45 min at 100V before visualizing the band.      
 
2.6.3.3 Measuring DNA concentration 
For estimating the amplified DNA concentration, a Qubit dsDNA HS Assay Kit 
(Thermo Fisher) was used as following: 
1.Dilute the dsDNA HS reagent in dsDNA HS buffer1: 200. Prepare enough working 
solution for all samples and standards. 
2. Pipette 190 µL of Qubit working solution to each of the standard tubes. Then 
add 10 µL of each standard to the appropriate tube, mix and vortex for 2-3 s.  
3. Pipette working solution into sample tubes to obtain a final volume of 200 µL in 
each tube.   
4. Add each sample to a tube containing the working solution, then vortex for 2–
3 seconds.  
5. Incubate for 2 min at RT. 
6. Read standard and sample concentrations on the instrument screen. 
DNA purification 
For DNA purification a PureLink™ Quick Gel Extraction and PCR Purification Combo 
Kit (Thermo Fisher) was used as follows: 
1. Add the gel piece containing the DNA fragment into the Spin Column inside a 
wash tube. 
2. Spin the tube for 1 min at >10,000 × g, then discard the filtrate and insert the 




3. Pipette 500–700 µL Wash Buffer 1 containing ethanol to the Spin Column. 
4. Centrifuge for 1 min at >10,000 × g, then discard the filtrate and insert the 
Spin Column into a new Wash Tube. 
5. Centrifuge again at maximum speed for 2–3 min to dry out any remaining Wash 
Buffer and ethanol. 
6. Place the Spin Column into an Elution Tube. 
7. Add 50 µL Elution Buffer to the Spin Column with avoiding the rim of the tube. 
8. Incubate for 1 minute at room temperature. 
9. Spin the tube at >10,000 × g for 1 min. 
10. Store the purified DNA at -20ºC for short term storage. 
 
2.6.3.4 Sequencing  
The purified PCR products were sent to the company for Sanger sequencing 
(Source Biosciences Inc. UK). The samples were packed with both forward and 
reverse primers frwBKVP1 (5′CCCCAACCAAAAGAAAAGGAGAGTGTCAC3′) and 
revBKVP1 (5′ GTCTTTCTGTGCCCCATCAAACACCCTA3′) and sent to the company 
after online submission. The sequencing data was referred electronically via E-
mail and the forward and reverse sequences were aligned and accessed with 
software that allows (BLAST) comparison with standard sequences. 
 
 
2.7 Statistical analysis 
Data in this thesis were mostly analysed by Prism Graph Pad version.6, MEGA, 
FLOW JO and SPSS software. One-way ANOVA and paired and unpaired t tests 

















3 Immune responses against BK virus in healthy 





BK virus (BKV) is a member of the polyomavirus family that was discovered in 
1971 (S. D. Gardner et al., 1971). The virus is an emerging opportunistic 
infectious agent that could co-evolve with its host and persist without any specific 
symptoms, as shown by its high distribution and low mortality rate. Despite its 
high seroprevalence only 19% of healthy donors shed BK virus in their urine after 
primary infection, which is mainly sub-clinical; the virus persists in the urinary and 
renal epithelium and establishes latency. 
In immunocompromised hosts, the virus can reactivate in the uro-epithelial tissue 
and cause viruria and viremia. The main cause of the immune dysfunction that 
leads to BKV reactivation is the initiation of immunosuppression therapy after 
transplantation in order to prevent post-transplant cell injury that ultimately leads 
to graft rejection. 
Currently, due to lack of effective anti-viral drugs for BKV, the keystone strategy 
in preventing BK reactivation is reducing the immunosuppressive therapy regimen 
while taking care to avoid acute rejection. Routinely, the recommended approach 
in most transplant centres after detecting BK viremia, is gradual reduction in 
immunosuppressive drugs in order to restore the immune defences against BKV, 
which comes with a risk of acute graft rejection. Unfortunately, only a few 
controlled trials have investigated management of BK viremia and BKV 
nephropathy (BKVN); (Hardinger, Koch, Bohl, Storch, & Brennan, 2010a; Puneet 
Sood et al., 2012). Moreover, adoptive T-cell transfer is one of the successful 
methods for reconstitution of the immune response against the virus. The method 
has shown effective clinical results with many chronic viruses such as CMV, EBV, 




cell epitopes. This would also require HLA matching of transferred T-cells from the 
donor and recipient.  
Cellular immunity plays an important role in BK virus clearance and controlling of 
BKVN in KT individuals. A considerable amount of literature has been published on 
the presence of a link or correlation between the specific cellular immune response 
and controlling BKV replication (P Comoli, Hirsch, & Ginevri, 2008; Dekeyser et 
al., 2015); the main debate is whether this mechanism depends on CD4 T-cells 
only or both CD4+ and CD8+ T-cells, which are directed to recognise 
endogenously expressed viral proteins in the context of MHC-class-I molecules.  
In common, most of the BKV studies are based on in vitro PBMC expansion/mixed 
lymphocyte peptide culture (MLPC); stimulating the immune cells using five BKV 
antigenic peptides so as to be able to detect even low number of BKV–specific T-
cells. A previous study identified the high sensitivity of the mixed pool method 
compared to using single pools (Trydzenskaya et al., 2011). Also, a recent study 
has used bioinformatics to predict 9mer peptide epitopes in the early viral gene 
(EVGR) presented by 14 HLA class-I molecules that are commonly found in North 
America and Europe; thirty-nine epitopes were confirmed experimentally using 
(INF-γ) enzyme-linked immune-spot assays, where early studies characterized 
BKV specific CD8 epitopes restricted to HLA A1, A2, A3, A24, B7 and B8 (G. 
Ambalathingal et al., 2017; Cioni et al., 2016). Moreover, the same group found 
that some BKV epitopes had significant homology with JCV; the same study and 
others suggested that a previous exposure to JCV may lead to cross-protection 
from BKV disease. This strong level of homology raises the possibility of 
development of immune monitoring tools that may apply to both BKV and JCV. 
Current approaches after identification of remarkable numbers of BKV- specific T-
cell epitopes should focus on expanding the HLA restriction alleles based on ethnic 
groups, which will be a useful monitoring tool for BKV disease, especially for 
regions other than North America and Europe (G. Ambalathingal et al., 2017). 
As previously mentioned the most useful approach in BKV management in most 
transplant centres is restoring virus specific immunity and avoiding the risk of 
graft rejection by reducing the immune suppression regimen (Smith et al., 1998). 




recovery from polyomavirus infection (Leboeuf et al., 2017b; Schachtner et al., 
2011).  
Generation of the humoral immune response to BKV could be a crucial tool in 
prediction of BKV viremia and the timeline of virus elimination post-transplant. 
However, most of the literature that studied BKV virus humoral response was 
based on a hemagglutination inhibition assay (Coleman, Gardner, & Field, 1973; 
De Stasio et al., 1979; DeStasio et al., 1980; S. Gardner, MacKenzie, Smith, & 
Porter, 1984; S. D. Gardner et al., 1971; HOGAN, BORDEN, McBain, Padgett, & 
Walker, 1980; W. A. Knowles et al., 2003; Shah, Daniel, Madden, & Stagno, 1980; 
Stoian, Hozoc, Iosipenco, Nastac, & Melencu, 1983) while some recent studies 
used ELISA assays to measure anti BKV titres. One of these studied by Bohl et al 
showed that donors’ pre-transplant antibody titres could predict duration of post-
transplant viruria (D. Bohl, Ryschkewitsch, Major, Storch, & Brennan, 2005) and  
Hariharan et al reported  a transitory correlation between elimination of BKV and 
development of immunoglobulin G (IgG) antibodies in recipient with biopsy proven 
BKV nephropathy (Sundaram Hariharan et al., 2005). 
The studies of this chapter were investigating cellular immune responses in renal 
transplant recipients with different status of virus replication, to an overlapping 
15 mer peptide pool from all virus antigens, specifically, interferon γ secreting 
cells, as well as in healthy subjects as a comparison, despite the low pathological 
potential. Additionally, monitoring immunoglobulin G responses to BKV VP1 
antigen, using an ELISA assay, enables for the evaluation of the presence of 
specific antibody immunity which could be an indication of previous infection in 










3.1 Study populations 
3.1.1  Healthy subjects  
Healthy volunteers aged from 18-74, both male and female who are members of 
the Department of Clinical Infection, Microbiology & Immunology, Ronald Ross 
building, were identified through an advertisement in the department monthly 
magazine. They were recruited to donate a urine sample after obtaining written 
informed consent. Project ethical approval was granted by the University of 
Liverpool Interventional Ethics Committee. 71 urine samples were collected in 20 
ml sterile containers and stored at -20ºC until the time of the experiment. Blood 
samples were collected from participants who tested positive for virus DNA and 
also from control urine negative subjects. 
3.1.2  Renal Transplant Patients  
Patients from the Renal Transplant Unit in the Royal Liverpool University Hospital 
were recruited and consented to donate 40 ml fresh blood and 20 ml urine sample. 
The blood samples were collected into heparin tubes then centrifuged for 30 min 
to separate PBMC and plasma, while the urine was stored at -20ºC for later PCR.  
 
3.2  BKV screening  
A total of 71 urine samples from healthy subjects, were tested for BKV Ab, then 
the presence of BK virus DNA in BKV IgG positives, using PCR (Fig 3.1). Thirteen 
(18.3%) were found to have been infected with BKV via the presence of serum 
BKV antibodies (Table 3.1). Four (30.7%) of them were urine BKV PCR positive, 
whilst the remaining 9 (69%) were found to be BKV PCR negative, with a median 
age of 48 and four of them were male volunteers without any known pathological 
problems. However, one of the male subjects is on monthly anti-TNF therapy for 
an arthritic condition.  
Regarding the renal transplant patients, the samples obtained were already 
confirmed positive or negative for BKV; the sample were categorised based on 
presence of BKV in the patient blood: BKV positive (n=9), BKV negative (n=12), 






Table 3.1. Baseline characteristics of healthy subjects. 
 BKV IgG + BKV IgG (-)  
n=13 n=58 
Age, mean of years (range) 48 (40-64) 34 (18-74) 
Male sex% 11(84%) 40 (68.9%) 
Pathological conditions  1 0 






Table 3.2. Baseline characteristics of renal transplant patients. 
 
Characteristics Total  BKV+ BKV (-) BKV historical  Pre-
transplant  
P value  
 n=33 n=9 n=12 n=10 n=2  
Age (mean) 53.7 55.6 60 58.3 41 NS 
Gender; male (%) 26 9(100) 7(58) 8(80) 2(100) NS 
Serum creatinine 
(mean) 
219 197 136 158 385 NS 
Re-transplant (%) 1 1 (11)     
Underlying diseases       
Polycystic kidney  7 3(33.3) 3(25) 1(10)  NS 
Obstructive uropathy  2  2(16.6)   NS 
Glomerulonephritis 5 4(44.4)  1(10)  NS 
Other  17 2(22.2) 7(58.3) 8(80)  NS 











Quantitation data for Cycling A. Green 
 
Figure 3.1.BKV qPCR plot 
 Illustrates the amplification of BKV DNA from healthy subjects’ urine samples. The red lines represent the PCR standards, the 




3.3 Healthy subjects  
3.3.1  BK virus antigen specific cellular responses in healthy controls. 
This study aimed to measure BKV specific cellular immunity and test the 
association between cellular and humoral immune responses to BK virus that could 
be a crucial tool in understanding the impact of BK virus reactivation post kidney 
transplant. A small but well-defined sample of healthy individuals was recruited 
and categorized into two groups: BK+ urine and BK- urine  
Initially, the range of the cellular response was measured by isolating PBMCs from 
whole blood samples, then cells were stimulated and incubated with BK virus 
immunogenic peptide pools. INF-γ production was then measured using an 
ELISPOT assay (Fig 3.3). Participants who were positive for urine BK DNA 




negative group (p<0.004). The number of spots in the negative control (cut-off) 
was subtracted from all the samples (Fig 3.2). 
  
Figure 3.2. Cellular responses to BKV peptides  
BKV specific INF-γ secreting cells using Enzyme-linked immune-spot (ELISPOT) responses to BKV after stimulation with BK 
overlapping peptide pools. The responses to overlapping peptide pools were measured by an interferon (IFN)-γ–ELISPOT 
assay. Responses are demonstrated in healthy people within the two categories: BK+ subjects with virus DNA in urine and 
anti BKV IgG, and BK- subjects with negative urine and anti BKV IgG. Points represent individual subjects, bars are means ± 
standard error of the mean, student t-test was used to compare the means.  
 
 

































Figure 3.3 Enzyme-linked immune-spot (ELISPOT) assay 
Elispot assays of samples of BKV + and BKV - subjects including negative and positive controls. Isolated PBMCs were 
stimulated with anti-CD3 antibody (positive control), unstimulated cells (negative control) and BKV- peptide stimulated 
cells. An ELISPOT assay in immunocompetent subjects with urine BKV, B immunocompetent subjects with negative urine 
BKV, bars indicate mean ± SD values, and the statistical significance was assessed using one-way ANOVA test (P < 0.0001). 
C. representative example of 1- positive control, 2- BKV positive subjects, 3- BKV negative subjects and 4- background wells 
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3.3.2  BK virus antigen specific humoral responses in healthy controls. 
 
BK virus-specific IgG was measured in 13 plasma samples from healthy 
participants: 4 with detected BKV in urine and 9 without, using a qualitative ELISA 
kit. Seropositive status was assigned if the optical density (OPD) of the ELISA was 
over the cut-off value. After testing the serological status (seropositive or 
seronegative), the antibody titres in the seropositive donors were estimated semi-
quantitatively. Our data showed that BKV IgG concentration was slightly higher in 
subjects with negative BK DNA urine mean 0.48±0.03 in comparison to positive 
urine with mean =0.4±0.2 (P=0.3776).  
 
Figure 3.4 . BKV serum IgG levels 
BKV IgG OD (450nm) in relation to BK in urine. Plasma samples from healthy donors with BKV positive (n=4) and negative 
(n=9) urine were tested for BKV IgG antibody using a sandwich ELISA. Box and whisker plots show 10-90 percentile and 
antibody levels are expressed as OD at (450nm). The statistical significance was assessed using student’s t-test (P= 0.3776). 
 
3.3.3  Correlation between humoral and cellular anti-BK responses.  
The levels of cellular and humoral immune responses to BK virus in healthy 
subjects were compared. There was a slight but not statistically significant 






























negative correlation between levels of cellular immunity and humoral immunity in 
both participant categories (p=0.4; Fig. 3.5). 
 
 
Figure 3.5 Correlation between BKV specific cellular immunity and anti BKV IgG in healthy subjects 
with or without BKV. 
The plot shows correlation between number of BKV specific INF-γ secreting cells and levels of anti –BKV antibody in BKV+ and 
BKV - immunocompetent donors. The optical density shows a slight but not significant negative correlation with increasing 







3.4  Renal transplant Patients 
3.4.1  BK virus antigen specific cellular responses in renal patients. 
Cellular immune responses were measured in PBMCs from different groups of 
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never had BKV, BKV+ and patients with resolved BKV infection. ELISPOT assays 
were performed to assess BKV specific T-cells after stimulating the cells with four 
BKV peptide pools. BKV specific immunity SFU was lowest in recipients with active 
BKV infection among the patient groups. Recipients who never experienced BKV 
replication after transplant showed higher specific cellular responses to BKV than 
BKV+ recipients (P<0.005). The patient group with historical BKV infection 
showed cellular immunity against BKV peptides that was higher than the BKV+ 
group but without reaching statistical significance (P<0.1). However, pre-
transplant kidney recipients demonstrated a difference between specific cellular 
immunity against BKV in comparison to post-transplant individuals; P<.001 in 
comparison to BK+ and P< 0.03 in comparison to the BK- group (Fig. 3.6).   
 
Figure 3.6.IFN-γ response of PBMC of KT patients  
2 pre-transplant patients, 9 BKV positive patients, 12 BKV negative recipients and 10 historical positive for BKV.  
  
Patients were categorized into four different groups based on BKV infection, stimulated with the BKV 
peptide pool and compared for SFU by ELISPOT assay. Unpaired t test was used to compare between 
the patient groups. * p< 0.05, ** p<0.005 
 
Next, the levels of anti-BKV antibody were assessed among the different patient 
groups; serum anti-BKV was found to be significantly higher in the post-transplant 
patients in comparison to the pre-transplant group (P<0.005). In BKV + 
























recipients, the observed anti-BKV levels were found to be significantly higher than 
in the pre-transplant group (p<0.0001) (Fig. 3.7). Similar results were found for 
the BKV-group and patients who resolved BKV after transplant (data not shown). 
Moreover, in post-transplant groups, statistical differences in anti-BKV levels were 
observed between patients with historical BKV infection and patients without 
reported BKV infection after transplant (p<0.005), whilst no difference in the anti-
BKV levels were seen between BK+ and BKV- groups (Fig. 3.7). Interestingly, 
there seems to be a group of 5 BK- patients with very low antibody levels, with 4 
in the pre-transplant group and one in the BKV (+) group.  
 
 
Figure 3.7.BK polyomavirus antibody response 
BKV specific IgG was measured in groups of renal transplant recipients: pre-transplant and post-transplant with positive, 
negative BKV and recipients with historical BKV infection. An unpaired t test was used to compare between the patient groups 
(** P<0.005 and *** P<0.00005). BKH = patients with a historical episode of BK viremia. 
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3.4.2  Correlation between BKV IgG level and urine viral load 
 
The relationship between BKV viral load and level of anti BKV IgG was investigated 
in some patients with active BKV virus, either viruria or viremia (n=12). A strong 
negative correlation was observed between the presence of virus DNA in the urine   
and the level of immunoglobulin G (r=-0.7, p<0.0005; Fig. 3.8). 
  
 
Figure 3.8. Correlation between BKV IgG level and urine viral load 
Plot of anti-BKV IgG against BKV viral load where only samples from recipients with active BKV viremia or viruria were 
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Controlling BKV reactivation is believed to be via the presence of T-cell dependent 
immune responses (P. Comoli et al., 2006; Lukacher, Moser, Hadley, & Altman, 
1999); therefore quantification of T-cell responses and  level of humoral response  
to virus would be of importance in guiding the levels of administered 
immunosuppressive therapies in BKV-positive patients and assessment of BKV 
specific cellular immunity and the level of anti BKV IgG in healthy donors using 
urine BK positivity as a marker for presence of virus. 
Here, the presence of BKV specific cellular immunity was assessed and evaluated 
by measuring T-lymphocyte IFN-γ secretion using an ELISPOT assay and humoral 
immunity using a semi quantitative ELISA. Immune responses were analysed in 
healthy control subjects who were found to be either positive or negative for BKV 
in their urine as a measure of infectivity and who are deemed immune competent. 
Additionally, the same responses were tested in different categories of renal 
transplant recipients based on detection of BKV DNA. 
The data showed a clear presence of BKV specific T-cell immune responses in 
healthy subjects with BKV detected in urine in comparison to healthy subjects with 
no virus detected, who had significantly lower levels. Dekeyser in a similar study 
utilising BKV seropositive healthy subjects reported that BKV specific immune 
responses could be detected in 71% of seropositive individuals, with 91% of the 
response mediated by CD4+ T-cells with only 31% mediated by CD8+ T-cells 
(Dekeyser et al., 2015). Moreover, the same observation was reported by others 
(Abate et al., 2010; Chanouzas, Small, Borrows, & Ball, 2018) when studying CMV 
specific cellular immune responses in uninfected patients with or without 
immunosuppression, which is applicable to our data as the T-cells have not 
previously encountered virus antigen if the subjects had always been BKV (-). 
However, it remains possible that our urine BKV (-) subjects had previously 
become infected with BKV and either eliminated the virus or it remained dormant, 
as we tested the urine as a marker for infection.  
The specific anti-BKV IgG levels among the above same two groups were similar. 
Interestingly, a negative correlation was reported between the presence of BKV 
specific cellular immune responses and anti-BKV IgG levels. The presence of BKV 




due to efficient immune surveillance in immune competent subjects who 
encountered the virus. As mentioned above, detection of similar levels of anti-BKV 
IgG in both groups could be due to previous elimination or latency of the virus in 
the urine of negative individuals as seroprevalence in the healthy population 
reaches up to 87% (A. Egli et al., 2009).  
In renal transplant recipients, the pathophysiology of BKV reactivation is still 
unclear and many factors have been suggested to influence the reactivation post-
transplant, either host dependent, virus dependent or exterior modulator 
dependent such as immunosuppression (H. H. Hirsch & Steiger, 2003).  
Our results indicated that patients with persistent or increasing BKV load (viremia) 
showed significantly lower BKV specific cellular immune responses compared to 
the other tested groups which could be a result of impaired immunity due to 
immunosuppression, agrees with the work of Comoli et al who showed that 
patients with ongoing viremia demonstrated the lowest response (P. Comoli et al., 
2006) and another very recent study (Bae et al., 2020a). This may be because 
the actively viremic patients have not had long enough to generate a strong 
cellular response to BKV in the presence of ongoing immunosuppression. As the 
historical group showed a good cellular response in comparison to the viremia 
group which suggests a relationship between recoveries of cellular immunity in 
parallel with resolution of viremia. Moreover, results were consistent with 
restoration of cellular immunity in response to reduction of immune suppression 
as patients with resolved viremia showed high cellular responses. Also, it is worth 
taking into account other factors that may influence cellular immunity such as age, 
sex and prescribed medications. 
Next, regarding anti-BKV IgG levels among the patient groups, humoral responses 
were detected in pre-transplant groups; however, significantly higher levels were 
observed in post-transplant groups: viremia patients, BKV negative patients and 
the group who had resolved virus infection regardless of the immunosuppression 
induction. 
However, in both the pre-transplant and BKV- groups there was a small subset of 
around 20% of patients with very low specific antibody levels. These may never 
previously have been exposed to BKV. Similarly, there were several patients in 




these were initially BKV (-) patients who had received a kidney from a BKV (+) 
donor and had not yet produced a secondary antibody response due to receiving 
immunosuppressive therapy. It would be of interest to test anti-BKV IgM levels in 
these patients as an indication of whether they have made a primary immune 
response to the virus. Specific anti-BKV secretory IgA levels would also be relevant 
as BKV infects the urothelium which is part of the mucosal immune system.    
In these investigations of both cellular and humoral immunity, it was observed 
that there is a relationship between anti-BKV IgG levels, urine BKV DNA and 
specific cellular immunity. It is proposed that the presence of virus, as detected 
by viral DNA, leads to induction of an anti-BKV IgG response during 
immunosuppressive therapy treatment (absence of cellular immunity) but this 
humoral response doesn’t seem to protect from virus reactivation and progression 
of BKV viremia. However, with the reduction of immune suppression cellular 
immunity is restored as supported by previous findings (Hammer et al., 2006; 











































4 Human leucocyte G expression after BKV infection 
 
Introduction  
In the early 1970s BK polyomavirus was initially identified from kidney  transplant 
recipients (KTR); the virus causes asymptomatic infection in early age with a 
seroprevalence up to 90% (Adrian Egli et al., 2009). Following primary infection, 
the virus establishes latency in the uroepithelial tissue. In immunocompromised 
patients the virus replicates and causes BKPyAN in 1-10% of recipients (Egli et 
al., 2007; H. H. Hirsch & Steiger, 2003). 
In this chapter, the hypothesis that HLA-G expression and soluble HLA-G both 
have a role to play in BKV immune evasion was tested. So, the expression of cell 
surface HLA-G and soluble plasma HLA-G (sHLA-G) were evaluated in PBMCs from 
healthy individuals with known BKV status and KTRs with BKV viremia to a BKV 
peptide pool. The participant urine samples were tested for BKV DNA using 
quantitative real time PCR (qPCR) and blood samples were collected from health 
subjects who were urine positive and KTRs with positive plasma, then PBMC 
isolated and stimulated with BKV peptides for three days before phenotyping the 
cells. 
4.1  Study Samples  
4.1.1 Healthy Subjects 
Healthy volunteers aged from 18-74, both male and female who work in the 
Department of Clinical Infection, Microbiology and Immunology were identified 
through advertisement in the department monthly magazine. They were recruited 
to donate urine samples after giving written informed consent. Project ethical 
approval was granted by The University of Liverpool Interventional Ethics 
Committee. 80 urine samples were collected in 20 ml sterile container and stored 
at -20ºC until the time of the experiment. Blood samples were subsequently 
collected from participants whose urine samples tested positive for BK virus DNA. 
4.1.2 Renal Transplant Patients  
Patients from the Renal Transplant Unit in the Royal Liverpool University Hospital 
were consented to donate 40 ml fresh blood samples, the samples were collected 





4.2 BKV screening  
Out of the 71 urine samples from healthy subjects that were tested, 5 (7%) 
tested positive for BKV DNA with variable viral loads and 75 (93.7%) were 




Figure 4.1.  Representative RT-qPCR amplification plot 
Fluorescent signal against the number of the cycles and generated standard curve by CT value vs the virus load concentration. 
Includes the amplified sample in the blue line, 4 quantitation standards in the red lines and negative control black line. The 

























4.3 Anti HLA-G antibody validation utilising the JEG-3 cell line -  
The monoclonal anti-HLA-G antibody used in the experiment was highly specific 
for HLA-G with no cross reactivity found with the other HLA molecules. This specific 
antibody has been validated using the choriocarcinoma cell line (JEG-3) known to 
express HLA-G (Yie, Li, Li, Xiao, & Librach, 2005). Cells were incubated in culture 
media for 30 min with either an isotype control antibody, the anti-HLA-G antibody 
or unlabelled. The cells were then acquired by Accuri C6 flow cytometry and 
analysed. The percentage of cells expressing HLA-G was found to be 87.47% while 
the background expression on the unlabelled cells was 0.68% (Fig. 4.2). The 
validation was performed by our laboratory and we used the same batch of the 
tested anti-HLA-G antibody as previously described (Fig. 4.2) (Z. Albayati et al., 
2017).  
 
   
Figure 4.2. Flow cytometry plot of JEG-3 carcinoma cells 
The cells were labelled with anti HLA-G antibody; the plots in order: gated cells, side against forward scatter, cells labelled 




4.4 HLA-G expression in healthy subjects  
 
4.4.1 HLA-G expression in BKV (+) healthy subjects (resting cells) 
Surface HLA-G expression on lymphocyte subsets and monocytes of 
immunocompetent participants with BKV DNA detected in urine was as follows: 
the population that showed the highest expression was monocytes with 
14.8%±15.5, followed by CD3+CD56+ cells with 9.3%±4.7, then 7.16%±4.2 for 
CD19+ (B-cells), whilst the cells that showed the lowest percentage were 
CD3+CD4+ and CD3+CD8+ T-cells with expression levels of 2.6% ±2.11 and 




Figure 4.3. Mean % of cells expressing surface HLA-G on resting PBMC. 



































4.4.2 HLA-G expression in BKV (+) healthy subjects PBMCs after culture with 
BKV peptide pool.  
 
After a 3-day incubation of isolated cells with BKV peptides, expression of HLA-G 
on the surface of the monocyte population was the highest among the PBMCs 
populations with 11.9%±3.7 followed by CD3+CD56+ T-cells with 8.55%±8.5, 
then CD19+ B-cells with 6.6%±2.7. CD3+CD8+ T cells showed the lowest 




Figure 4.4. HLA-G expression chart of PBMCs after culture with BKV peptide pool, each bar 
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4.4.3  HLA-G expression in resting and cultured PBMCs from BKV (+) subjects 
 
After three days incubation of cells with BKV peptides, the expression of HLA-G 
was compared in the cultured cells and resting cells to evaluate the effect of the 
BKV peptide pool on the various cell populations. It was observed that the 
proportion of surface HLA-G+ cells increased in some of the lymphocyte 
populations such as CD3+CD4+ and CD3+CD8+ cells but this was not significantly 
different (p=0.06 and p=0.08, respectively). Other populations showed no 
difference in HLA-G expression before and after culture (p=0.8, p=0.86 and 















Figure 4.5. Flow cytometry gating strategy  
Initially, FSC vs SSC gating was used to identify the distinct cell types (lymphocytes). Then, A forward scatter height (FSC-H) 
vs. forward scatter area (FSC-A) density plot used to exclude doublets. After that, two parameter density plots were 
generated with two axis that represent particular markers within our sample to identify CD3+CD4+ cell populations. Finally, 







Figure 4.6. Comparison of surface HLA-G expression on resting PBMCS with and without culture with 
BKV peptides,  






4.4.4 Expression of HLA-G on resting PBMCs from BKV (-) subjects.  
 
Likewise, the expression of HLA-G was evaluated in healthy subjects who were 
found to be urine negative for BKV DNA. CD14+DR cells showed the highest levels 
of expression of HLA-G with mean of 29.9%±14 (P<.0001), whilst the other 
populations showed relatively lower expression; CD3+CD4+ (2.76%±3.3), 
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Figure 4.7. HLA-G expression on resting PBMCs isolated from healthy subjects with BKV - urine. One-







4.4.5  Expression of HLA-G on peptide-stimulated PBMCs from BKV (-) subjects  
 
As performed previously with the positive subjects, PBMCs from the BK (-) group 
were stimulated with BKV peptides to assess any changes in the expression of 
HLA-G on the cell surface. Generally, the cell subsets show different levels of 
expression; a greater proportion of CD14+DR cells expressed HLA-G (27%±22.3) 
whilst CD3+CD4+ expressed the lowest (3.4%±3.3). Mean percentage of other 
cell types expressing HLA-G were: 10.4%±12, 6, 5%±8.6, and 4.6%±5.8 for 
CD3+CD56+, CD3+CD8 and CD19+ cells, respectively. The difference between 
CD14+DR+ cells and the other cell populations was statistically significant 































Figure 4.8. HLA-G expression on PBMCs isolated from healthy BKV (-) subjects and cultured with BKV 
peptide.  




4.4.6 Comparison of HLA-G expression in resting PBMCs from urine BK (-) 
healthy subjects and after culture with BKV peptides  
 
Here, HLA-G expression before and after BKV peptide stimulation was compared 
in PBMC isolated from urine BKV (-) individuals. A slight upregulation of HLA-G 
expression was observed after incubation with virus peptides in most of the cell 
populations, including CD3+CD56+ and CD3+CD8+ cells. However, the 
differences were not statistically significant after testing using a standard paired 





























Figure 4.9. Comparison of surface HLA-G expression on resting PBMC and after culture with BKV 








4.4.7  HLA-G expression by resting PBMCs in urine BKV (-) and BKV (+) 
subjects  
 
After assessing HLA-G expression in BKV (+) and BKV (-) subjects, the two groups 
were compared for HLA-G expression regarding resting cells. Some 
subpopulations from subjects with BKV (+) urine exhibited higher HLA-G 
expression levels in comparison to the BKV (-) group, such as CD3+CD8+, 
CD3+CD56+ and CD19+ cells. However, some populations showed no difference 
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BKV (-) subjects expressed more HLA-G than those from BKV (+) subjects (Fig. 
4.10). However, none of these differences reached statistical significance. 
 
Figure 4.10.  HLA-G expression on resting PBMCs subpopulations from healthy subjects with BKV + 
and BKV- urine. 






4.4.8 HLA-G expression by PBMCs in BKV (-) and BKV (+) subjects (after 
culture with BKV peptides 
 
On the third day of incubation with BKV peptides, HLA-G expression was assessed 
in two tested groups. The percentage of HLA-G+ cells is illustrated in Figure 4.11 
Some subpopulations from the urine BKV (-) group showed an elevation of HLA-
G expression in comparison to the BKV (+) group: CD3+CD8+, CD3+CD56+, and 
CD14+DR cells. However, T-helper lymphocytes and B-cells showed no difference 
in HLA-G expression between the two groups.  
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Figure 4.11. HLA-G expression on PBMC subpopulations from with BKV + and BKV- urine after culture 
with BKV peptides. 





4.5  HLA-G expression in KTR recipients  
 
After investigating HLA-G expression in immunocompetent subjects with BKV 
infection, we went on to study the same expression on post renal transplant 
recipient with BKV infection, as the main difference between healthy and patient 
groups is administration of immune suppressants and consequently attenuation of 
the normal immune response.    
Four patients with confirmed post-transplant BKV viremia and three recipients who 
never tested positive for BKV infection after transplantation were evaluated for 
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with BKV peptides for three days and HLA-G expression was compared in the 







4.5.1 HLA-G expression on resting PBMCs from KTR with BKV viremia 
 
HLA-G cell surface expression in transplant patients was found to be significantly 
higher than in healthy subjects. However, the expression was found to be variable 
among lymphocyte and monocyte subpopulations. CD3+CD56+, CD14+DR and 
CD3+CD4+ cells showed higher expression, 68%±12, 55%±7.4 and 52%±21,4, 
respectively, whilst CD3+CD8+ and CD19+ cell HLA-G expression was found to 
be 38%±8.3 and 48%±9.2, respectively (p=0.06 using one-way ANOVA test). 
 
 
Figure 4.12. HLA-G expression on resting PBMCs from renal transplant recipients with BKV viremia. 






































4.5.2 Comparison of HLA-G expression in resting cells of healthy donors and 
transplant patients. 
Here, HLA-G surface expression was compared between healthy subjects with BKV 
DNA and renal recipients with BKV viremia, in various subsets of lymphocytes and 
monocytes. Most lymphocytes subsets show that transplant patients with BKV 
viremia express higher levels of HLA-G compared to healthy individuals; 
CD3+CD4+ p=0.011, CD3+CD8+ p=0.001, CD3+56 p=0.0006, CD19+ p=0.001 
and CD14+DR p<0.005. 
 
 
Figure 4.13. Comparison of Surface HLA-G expression in healthy BK+ donors and renal recipients with BKV viremia. 
Multiple t –test was used to compare the mean of surface HLA-G levels in lymphocyte subsets and monocytes.  
  
 
4.5.3 HLA-G expression in PBMCs cultured with BKV peptides. 
 
After three days culture of the patient’s lymphocyte subsets with BKV peptides to 
measure HLA-G expression on monocytes and some lymphocyte subsets; HLA-G 
expression was generally found to decrease in comparison to the resting cells; the 
highest expression was reported on CD3+CD56+ sub-populations with 47%±28.9 
followed by CD14+ 43%±3.1, then CD3+CD8+, CD19+ and CD3+CD4+ with 
35%±13.7, 30%±15.5 and 27%±11.3, respectively (P= 0.4) 
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Figure 4.14 HLA-G expression on PBMCs from renal transplant recipients with BKV viremia, cultured 
with BKV peptides.  







4.5.4 Comparison of HLA-G expression on resting and cultured PBMCs from KTR 
individuals with BKV viremia. 
 
Next, here we compared the expression between resting and cultured cells to 
identify whether HLA-G expression patterns could be altered on specific cell types 
in KTR patients presenting with BKV viremia. Interestingly, in patients presenting 
with BKV viremia we could identify a decrease in HLA-G expression after the 
incubation with BKV peptides even though this elevation was not significant except 





































Figure 4.15. Mean proportions of HLA-G+ cells in subpopulations of PBMCs resting and post culture 
with BKV peptides. 







4.5.5 HLA-G expression in resting cells of KTR individuals who never 
demonstrated post-transplant BKV.  
 
Similar to the viremia recipients, HLA-G was evaluated on monocytes and 
lymphocyte surfaces of PBMCs isolated from recipients who never had a BKV 
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leucocyte sub-populations with 51%±6.0 CD3+CD56+ and CD19+ cells showed 
approximately the same levels of HLA-G expression, 32%±3.6 and 31%±2.5 
respectively. CD3+CD4+ and CD3+CD8+ were found to be the lowest with 
13%±3 and 11%±2.3, respectively (P<0.0001; Fig 4.15). 
 
 
Figure 4.16. HLA-G expression on resting PBMCs isolated from renal transplant recipients who never 
had a BKV episode after transplantation. 






4.5.6 HLA-G expression in PBMC from KTRs cultured with BKV peptides who 
never demonstrated post-transplant BKV 
 
Cell sub-populations from recipients who never demonstrated BKV infection after 
transplantation showed variable HLA-G expression patterns after culture with BK 
































by CD3+CD56+ and CD19+ cells with relatively similar expression of 37%±2.4 
and 35%±4.2 respectively. The lowest expression was reported for CD3+CD8+ 
and CD3+CD4+ sub-populations with means of 14%±0.49 and 12%±0.7, 




Figure 4.17. Histogram of mean %HLA-G+ cells in PBMC from KTRs who never a BKV episode had 
cultured with BKV peptides.  






4.5.7 Comparison of HLA-G expression on resting and cultured PBMC with BKV 

































After comparison of HLA-G expression pre- and post-stimulation with BKV peptide, 
a slight upregulation of expression after induction with the virus antigens was 
observed in most of the PBMC sub-populations. However, no statistically 
significant difference was observed after using a paired t-test (Fig. 4.17). So, 
among the never had BKV recipients the HLA-G expression was not altered with 
incubation with BKV peptides  
 
 
Figure 4.18 Comparison of surface HLA-G expression on resting PBMC and after culture with BKV 








4.5.8 HLA-G expression on resting PBMCs in KTR individuals with or without BKV 
viremia 
After comparison of HLA-G expression between KTRs who never developed BKV 
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viremia and without, to identify the influence of the BKV viremia on HLA-G 
expression. In general, the viremia group demonstrated a higher percentage of 
HLA-G-expressing cells in comparison to the control group. CD3+CD8+ T-cells 
showed a significant difference between the two groups of recipients (p<0.001) 
and the same was found for the CD3+CD56+ population (p<0.001). Other cell 
populations such as CD3+CD4+ and CD19+ also showed a smaller but still 
significant difference in HLA-G expression patterns (p<0.05). However, the 
expression on monocytes did not differ between the tested groups (Fig. 4.18). 
 
Figure 4.19. Histogram illustrating the HLA-G expression in resting PBMC. 
PBMC isolated from two groups of renal transplants recipients: with BKV viremia and without. Paired multiple t test was used 






4.5.9 HLA-G expression on PBMC cultured with BKV peptides in KTR individuals 
with or without BKV viremia. 
Like the resting cells the cultured cells showed differences in HLA-G expression 
between recipients with BKV viremia and the control group; patients with BKV 
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had group. Interestingly, higher proportions of all tested lymphocyte sub-
populations were found to express HLA-G in the viremia group after culture with 




Figure 4.20 Histogram illustrating the HLA-G expression in PBMC from KTRs cultured with BKV 
peptides  
PBMC were isolated from two groups of renal transplants recipients: with BKV viremia and without. Paired multiple t test was 
used to compare between the tested groups. p=0.1 CD3+CD4+, p=0.2 CD3+CD8+, p=0.66 CD3+CD56+, p=0.71 CD19+ and 
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Figure 4.21. Flow cytometry overlay Histogram illustration of HLA-G expression on CD3+CD4+ T lymphocytes. 
Healthy donor with BKV shedding shown in orange and renal recipient WITH BKV viremia in blue.  
 
Table 4.1. Summary of significant differences in HLA-G expression in the tested groups and the cell 
subpopulations. 
 
Figure#  Change Significance  Study group Cell population  
3  no Healthy BK+ (resting)  
4  no Healthy BK+ (cultured)  
5 Increase no Healthy BK+ (resting /cultured)  
6  yes Healthy-BKV- (resting) CD14+DR 
7  Yes  Healthy-BKV- (cultured) CD14+DR 
8 Increase no Healthy-BKV- (resting/cultured)  
9 Increase 
(BKV+) 
no Healthy BKV+/BKV-(resting)  
10 Increase 
(BKV-) 
no Healthy BKV+/BKV-(cultured)  
12  no Patient BK+(resting)  
13  no Patient BK+(cultured)  
14 Increase 
(resting) 
no Patient BK+ (resting/cultured  
15  Yes Patients-BK-(resting)  CD14+DR 
16  Yes Patients-BK-(cultured) CD14+DR 
17 Increase  no Patients-BK- (resting/cultured  
18 Increase Yes Patients BKV+/BKV- (resting CD3+CD4+ 





4.6  Soluble HLA-G 
4.6.1 Soluble HLA-G titres in healthy subjects 
 
Here, we tested the influence of BKV on plasma soluble HLA-G concentrations, so 
our observations may contribute more understanding of the role these molecules 
contribute in BKV infection.  Using a specific ELISA kit, plasma soluble HLA-G 
(sHLA-G) was measured from healthy subjects’ plasma with BKV (+) or BKV (-) 
tested urine. Median plasma sHLA-G titres in individuals with BKV (+) urine was 
64.7 U/ml whilst it was slightly higher 68.752U/ml in the BKV negative group with 
no statistically significant difference between the two groups (p=0.6; Fig. 4.22). 
 
 
4.6.2 Soluble HLA-G titres in KTR individuals  
 
After evaluation of cell surface HLA-G expression, we investigated the expression 
plasma soluble HLA-G in the same study groups: healthy subjects and post renal 
transplant recipients. 
As in the healthy subjects, plasma (sHLA-G) was measured in renal transplant 
recipients with BKV viremia (n=4) and recipients who never had viremia (n=5). 
Median plasma (sHLA-G) titre in viremia recipients was found to be 192 U/ml 
whilst in the BKV (-) group was found to be 214.3 U/ml, although this did not 






Figure 4.22 Levels of sHLA-G in healthy subjects with (n=4) and without (n=5) urinary BKV.  






Figure 4.23. Levels of sHLA-G in renal transplant recipients with BKV viremia (n=12) and without 
(n=7).  
Patients without BKV viremia show similar levels of sHLA-G in comparison to viremia patients and where the middle line 
























































Figure 4.24. Comparison of plasma sHLA-G levels between healthy controls and renal transplant 
patients with or without BKV viremia. 
The graph above demonstrates the difference in sHLA-G levels in healthy donors and renal transplant recipients as; patients 
show a significant increase in the plasma HLA-G in comparison to the healthy donors.  The middle line represents the median. 




4.7  Discussion 
It is well known that the immune system has efficient mechanisms of eliminating 
viral infections and that some viruses have developed several strategies to evade 
host immune responses. The HLA-G molecule has been reported to influence viral 
escape from immunity (H.-X. Chen et al., 2011; Gazit et al., 2007). This molecule  
aids viruses in immune evasion and protecting allografts using two proposed 
mechanisms; either: inhibition of NK and CD8+ T-cells cytolytic function, or 
suppression of CD4+ T-cell allo-proliferative responses, that can both be 
responsible for graft rejection (Rouas-Freiss, LeMaoult, Moreau, Dausset, & 
Carosella, 2003). Here, the expression of cell surface HLA-G and plasma soluble 
HLA-G (sHLA-G) was investigated in groups of healthy subjects with and without 
BKV in their urine and renal transplant patients with BKV viremia as well as those 
who never demonstrated BKV infection. 
Our findings show that there was no significant difference in HLA-G cell surface 






























urine BKV (-) subjects, except for the monocyte population that demonstrated 
higher levels of expression of HLA-G among all PBMCs populations in both healthy 
groups. Regarding PBMC cultures stimulated with BKV peptides, HLA-G expression 
was shown to be slightly higher after incubation with BKV peptides in BKV (-) 
individuals. Furthermore, even though there was no significant difference, BKV 
(+) subjects were found to have a higher proportion of HLA-G+ cells than the 
negative subjects. In vitro, Albayati et al showed that HLA-G surface expression  
increases on several leucocyte subsets with in vitro immune stimulation after 7 
days of incubation with CMV AD169 protein extract (Zaid Albayati et al., 2018) 
This observation agrees with a study describing the role of HLA-G in HIV infection, 
where it has been suggested that monocytes of HIV-1 infected patients express 
higher levels of HLA-G than a control uninfected group (Lozano et al., 2002). Also, 
an additional study supports our finding that CD4+ HLA-G+ and CD8+HLA-G+ 
cells could be found in the peripheral blood of healthy subjects in low numbers 
during inflammation (Feger et al., 2007). Further studies have also illustrated the 
role of HLA-G upregulation in controlling host immune responses following viral 
infection (Cordero et al., 2009; da Silva et al., 2014). Even though our findings 
do not show a significant difference in HLA-G cell surface protein expression on 
other lymphocyte populations, it remains a possibility that the slight upregulation 
observed may become statistically significant when increasing the sample size. 
In the field of solid organ transplantation, HLA-G plays a vital role in modulation 
of induced immune responses. It may play a two-fold role; induction of HLA-G 
after transplantation has been shown to increase graft survival by down-regulating 
host alloimmune cells but on the other hand it may help viral immune evasion 
(Lazarte, Adamson, Tumiati, & Delgado, 2018). In reviewing the literature, many 
studies have investigated the role of HLA-G in the context of viral infections, and 
many studied its importance after solid organ transplantation (Créput et al., 2003; 
Creput et al., 2003; Rouas-Freiss, Naji, Durrbach, & Carosella, 2007). Regarding 
transplantation, most studies have discussed the role HLA-G expression can play 
on graft survival. One study revealed that in transplant recipients infected with 
CMV, those carrying genotypic restrictions relating to lower HLA-G expression 
patterns had a higher incidence of acute organ rejection (Z.-K. Jin et al., 2012).  
Here we investigated the influence of HLA-G induction on BKV viremia patients 




significant up-regulation of HLA-G cell surface expression in comparison to those 
individuals who never demonstrated BKV infection, either in resting cells or after 
culture with BKV peptide; particularly CD8+ cytotoxic T-cells and CD56+ T-cell 
populations. Similar to the healthy subjects, the highest expression of HLA-G+ 
among all subpopulations was reported on the monocyte fraction, which would 
potentially be able to suppress the function of cells expressing ligands for HLA-G. 
Also, no significant difference was observed with or without incubation with BKV 
peptides. These findings are consistent with those previously described (Z.-K. Jin 
et al., 2012) with regards to a role of HLA-G in CMV infected kidney recipients. It 
is possible that whole or live virus particles would be required to stimulate an 
increase in HLA-G expression in vitro rather than just the peptide pool used here.   
Moreover, our data reported no significant differences in plasma sHLA-G 
concentrations between BKV (+) and BKV (-) healthy subjects. Additionally, no 
difference was observed between viremia renal transplant patients and those 
without BKV viremia. However, in comparison of plasma sHLA-G between healthy 
subjects and renal transplant recipients a remarkable difference was observed 
between the two groups as the concentration was significantly higher in the 
transplant patients. The findings could be explained by the fact that transplant 
recipients were treated with immunosuppressive drugs after transplantation, in 
addition to BKV viremia the combination of the two factors could consequently 
lead to the up-regulation of sHLA-G as previously proposed (Akhter et al., 2012; 
Levitsky et al., 2009) (Zaid Albayati et al., 2018). Any role of HLA-G in suppressing 
immune responses to BKV or, in transplant patients, preventing rejection, would 
be dependent upon cells expressing any of the ligands for HLA-G.    
In conclusion, based on our knowledge this is the first clinical report describing 
the impact of cell surface and soluble HLA-G expression patterns regarding active 
BKV infection in renal transplant recipients. Our study demonstrates that higher 
proportions of monocytes express HLA-G than other lymphocyte subsets. 
Furthermore, patients with active BKV infection showed dramatic increases in HLA-
G expression in comparison to recipients who did not encounter infection post-
transplantation. And finally, no difference was observed in plasma sHLA-G levels 






























5 BK virus antibody titres in post renal transplant recipients  
 
Introduction 
BK Polyomavirus infection is an asymptomatic infection that is mainly acquired at 
an early age; the virus seroprevalence reaches up to 90% within the healthy 
population and decreases with age. After primary infection the virus establishes 
latency in urothelium and tubular cells which is associated with the long-term 
presence of anti-BKV IgG in the serum and transitory excretion of the virus in 7-
55% of healthy subjects’ urine (H. H. Hirsch & Randhawa, 2013; R. Sharma et al., 
2016). 
In the absence of proper immune surveillance, some virus infections, including 
BKPyV, may establish reinfection. In solid organ transplantation, induction of 
immunosuppressive therapy is essential to prevent rejection and graft loss, 
however, it enhances conditions for opportunistic viruses such as polyomaviruses 
and herpesviruses to replicate in the absence of an optimal immune response. 
Reactivation of the virus after transplantation without proper immunity leads to 
BKV viremia and progression of BK disease. 
BKV may cause haemorrhagic cystitis in hematopoietic stem cell transplant 
recipients and BKV-associated nephropathy (BKVAN) in kidney transplant 
recipients. However, as yet, no standard method is available to predict BKV 
infection after transplantation and the most effective treatment to-date is periodic 
monitoring of the recipient blood for BKV DNA and reduction of 
immunosuppressive therapy when viremia is detected (Hardinger, Koch, Bohl, 
Storch, & Brennan, 2010b; H. H. Hirsch et al., 2005). 
In renal transplant recipients, the prevalence of detected BKV DNA from urine has 
been reported to be 30–57%, slightly higher than in healthy subjects (Adrian Egli 
et al., 2009). Whereas the frequency of BKV detection in blood ranges from 15-
30% among renal transplant recipients, only 1-10% of these patients were 
reported to develop BKVAN and graft rejection (H. H. Hirsch & Steiger, 2003; P. 




BKV disease and identification of recipients at risk mainly rely on detecting virus 
DNA in blood, as the presence of BKV viruria does not necessarily mean 
development of BKV disease unless virus load exceeds 1x104 copies/ml (H. H. 
Hirsch & Steiger, 2003). 
Many factors have been suggested to increase risks of BKV viremia and BKVAN; 
either pre-transplant factors such as immunosuppressive therapy regime, type of 
transplant, age, sex, ethnicity, HLA mismatch, acute rejection episodes, 
underlying diseases and pre-transplant organ cold and warm ischemic time (D. L. 
Bohl et al., 2008; D. L. Bohl et al., 2005; H. H. Hirsch et al., 2006). Or post-
transplant factors such as tacrolimus treatment and anti-rejection drug treatments 
(H. H. Hirsch et al., 2002). 
Several studies have suggested an association between pre-transplant anti-BKV 
sero-status and the recipient’s infection status (D. L. Bohl et al., 2008; S. 
Hariharan et al., 2005; Randhawa et al., 2008). However, the risk of high or low 
pre-transplant anti-BKV levels (titres) has not been clearly determined. 
Here, we hypothesise that recipient’s pre-transplant anti-BKV IgG levels and 
identification of some recipient HLA types may help in a patients’ risk stratification 
and pre-transplant assessment. We therefore aimed to 1-Measure anti BKV 
antibody levels before and after transplantation to test prior exposure and changes 
in antibody responses in relation to any subsequent development of viremia. 2- 
Compare the incidence of BK viremia in post renal transplant patients expressing 
different HLA types and with different levels of pre–transplant anti-BK titres. 
In this chapter, pre-transplant serum samples from renal transplant recipients had 
been collected prospectively. The tested groups were identified as recipients with 
confirmed post-transplant BKV viremia and recipients with BKVAN. Three different 
samples were collected from each recipient: pre-transplant, during the onset of 
BKV viremia and post-viremia, preferably more than one year from time of 
transplant. IgG antibody levels were evaluated quantitatively using standard 
ELISA with recombinant antigen not cross reacting with other polyomaviruses such 






5.1 Subject samples 
Demographic baseline data were notably similar among the study groups: viremic 
>1000 copies/ml and the never had viremia group. From a total of 38 renal 
transplant recipients, 18 (47.0%) developed viremia after transplantation with an 
average virus load of 5.3x103 copies/ml and peak viremia of 10x104 copies/ml 
within the first year of transplantation, 15 (39.4%) never had detectable BKV DNA 
from time of transplant until the end of the study and 5 (13.0%) detected with 
sustained low virus load. Only three (16.6%) cases from the viremia group who 
developed BKVAN, and 6 cases of acute rejection were found; half of it were due 
to complications of BKVAN and the other half due to other cases (Table 5.1). No 
significant difference was observed between the study groups in relation to age, 
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4(26.6) 1(5.8) 0 NS 1(6.6) 0 NS 
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70.9 71.5 40 NS 12(80) 3(100)  
Simulect 
 









4(16) 2(28) 1(20) NS 1(6.6) 1(30)  
Azathioprine 
 





NS; no significance differences between the recipient’s groups. MMF; 
mycophenolate mofetil therapy. TAC; tacrolimus. The data are shown as mean± 
standard deviation or percentage. The P-value was calculated using student`s t 


















2(8.3) 2(28) 1(20) NS 5(30) 1(30)  
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5(20) 1(5) 0 
 








0.88±.58 0.88±.78 1±.7 NS 0.92±.37 1  
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0.77±.54 0.77±.83 0.4±.54 NS 0.84±.3 0.66±.033  
DR 
 
0.66±.68 0.44±.72 0.6±.54 NS 0.92±.57 0.66±33 0.4 
A+B+DR 
 


















5.2  Specific anti-BKV antibody response  
To investigate prevalence of pre-transplant anti-BKV IgG and the association 
between pre-transplant anti-BKV levels and development of BK viremia and 
BKPyAN, a sandwich ELISA test was used to measure anti-BK-IgG. Our data 
indicated that 10 (66.6%) of the never had viremia group were anti-BKV IgG 
positive and up to 17 (94.0%) of recipients who developed BK viremia were anti-
BKV IgG positive, whereas all the patients who developed BKVAN were anti-BKV 
IgG positive (Table 5.2).  
Pre-transplant mean anti-BKV IgG levels in recipients with viremia were found to 
be lower in comparison to those who never had BKV viremia: 6.87±0.32, and 
7.704±0.31 respectively, whilst the mean in patients who developed BKVAN was 
found to be 7.5±0.94 (p=0.14; Fig. 5.1).  
Post-transplant mean anti-BKV IgG levels in recipients with BK viremia was 
significantly higher in comparison to the never had viremia group 10.21±0.5 vs. 
4.627±2.9. The mean was also higher in patients who developed BKVAN in 




Table 5.2. Comparison of pre- and post-transplant BKV Ab titre in renal transplant recipients with 
viremia and patients who never had viremia.   







post operation >1 year P- 
value 
Never BKV 66.6 
 
7.704 ± 0.31 













BVPyAN 100  7.5±0.94 
 
    10.50±0.23 
 
  <0.04 

















Figure 5.1. Mean titres of pre-transplant anti-BKV IgG 
 Antibody in pre-transplant recipients who developed BKV viremia following transplant. One-way ANOVA test was used to 
compare the mean antibody titres between the groups (P=0.14), N=38. 
 
 






























Figure 5.2 Mean titres of post-transplant anti-BKV IgG 
Antibody levels in post-transplant recipients who developed BKV viremia after the transplant. One-way ANOVA test was used 
to compare the mean antibody titres between the groups (P<0.05), N=28, while p<.0005 between never BKV group and BKV 
viremia group and p<.0005 between never BKV group and BKPyAN group using a t-test. 
 
 
Figure 5.3. Pre- and post-transplant anti BKV titres. 
In three different groups of renal transplant recipients; never had BKV viremia, with BKV viremia and recipients with BKPYAN. 
Multiple t-test was used to compare the means: p< 0.0005 for viremia patients, p<0.006 for recipients with BKPYAN and p<0.6 
in never BKV group.  


























E v a lu t io n  o f  p re -  a n d  p o s t tra n s p la n t  a n t i B K V  t ite r





























P re -tra n sp la n t








5.3 Pre-transplant and post-transplant follow up  
To monitor the level and change in anti-BKV IgG levels in recipients who developed 
BKV viremia after transplantation, levels of anti-BKV specific antibody in each 
patient were measured at three different time points: pre-transplant, onset of BKV 
viremia and after virus clearance. No significant change was observed in mean 
pre-transplant antibody levels 4.980±2.70 and one-year post-transplant antibody 
levels were 4.627±2.90, in never had BKV recipients with calculated P-value of 
0.77 (Fig 5.4B)  
However, in the viremia group the observed mean pre-transplant antibody level 
was found to be 6.24, then remarkably increased to 9.421 during BK viremia, with 
CI difference of (-4.494 to -1.857) and with a calculated p<0.00001 between the 
two groups. Comparing the level from the onset of viremia and after virus 
clearance, post-viremia mean antibody was found to be elevated to 10.21 with CI 
difference of (-2.104 to 0.5324) and a calculated p=0.8 (Fig. 5.4A). Despite the 
virus clearance from recipient plasma after viremia the antibody titres remained 
high and even closer to the viremia status (p=0.83). In contrast with the never 
BKV group the mean antibody titre was slightly lower than the pre-transplant level 








Figure 5.4. BKV antibody titre change in recipients 
A Patients with post-transplant BKV viremia. B BKV antibody titre changes in recipients who never developed BKV viremia 
after transplantation. For the post-transplant BKV viremia group, the antibody was measured prior to the transplant, at the 
onset of the viremia and after virus clearance; each box represents the interquartile range. P-value calculated using t- test. 
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Figure 5.5. Difference in BKV IgG antibody titres.  
Among pre- transplant patients, onset of viremia and one-year post in each individual recipient who developed BKV viremia. 
Blue circular points represent mean antibody titres pre-transplant, red triangular points at the onset of the viremia and green 
circular points shows antibody titres after one year of the transplant. Mean Ab titres differed significantly (p<0.001) in the 





5.4 Risk of individual Human leukocyte antigen (HLA) alleles in 
transplant patients developing BKV DNAemia and viremia  
Major histocompatibility complex (MHC) contains the genetic loci that are 
responsible of foreign tissue or organ rejection, and HLA molecules are the human 
MHC. Class I HLA are expressed on most nucleated cells, however class II is only 
expressed on B lymphocytes, antigen-presenting cells (monocytes, macrophages, 
and dendritic cells), and activated T lymphocytes (Choo, 2007). HLA molecules 



























play a role in the immune cells antigen identification, particularly natural killer 
cells (NK) and cytotoxic T-cell activation, however the exact role of HLA alleles in 
BKV infection and reactivation is still unclear. Here, we determined the risk of 
some HLA alleles in development of BKV viremia.  
As described above, a cohort of post renal transplant recipient were recruited for 
evaluation of pre-transplant potential risks of BKV viremia, frequency of variant 
HLA alleles was investigated in two patient categories; kidney transplant recipient 
(KTR) individuals with BKV viremia and KTR individuals without BKV viremia, 
patients’ HLA- A, B and DR data were collected from the hospital database. Alleles 
present in the patient groups at high frequency were chosen for more detailed 
analysis. The data showed that some HLA alleles were highly frequent in recipients 
with BKV viremia, including HLA-A1, HLA-A2, HLA-B44, HLA-DR1, HLA-DR4 and 
HLA-DR15 with others more frequent in non-viremic recipients, including HLA-B8 
and HLA-DR13. 
A total of 17 recipients who were positive for the HLA-B44 allele; 14 (82%) of 
them developed BKV viremia in comparison to three without viremia (p=0.02). 
Furthermore, 11 (91%) recipients of the 12 positives for the HLA-DR15 allele 
developed BKV viremia over only one without viremia (p=0.01). Conversely, 5 
(71%) of patients were positive for the HLA-B8 allele and 4 (80%) of HLA-DR13 
positive individuals demonstrated no virus replication (p=0.2 and p=0.15, 
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To study the association between the recipients’ HLA allele status and 
development of BKV viremia, a Kaplan-Meier survival curve was generated to 
evaluate the risk of BKV viremia after a two-year period following transplantation. 
HLA-B44 and HLA-DR15 alleles were found to be significantly associated with the 
risk of developing BKV viremia (p=0.001 and p=0.02 respectively; Fig. 5.6 and 
5.7). 
Furthermore, a multivariable (Cox regression) analysis was performed to identify 
risk factors that may be associated with the development of BKV viremia, factors 
such as age, sex and MHC class-l and -ll were tested (Table 5.4). HLA-B44 and 
HLA-DR15 showed significant association with viremia (HR: 0.296, 95%CI: 0.11-
0.73, P=0.009) and (HR: 44, 95%:0.18-1.08 P= 0.07). Male gender showed a 




p=0.08). However, recipient’s HLA-A2 status, age or HLA mismatch was not 
associated with the risk of developing BKV viremia. 
    
 
Table 5.3. Frequency of HLA alleles in transplant recipients in relation to BK viremia. 
The table illustrates the frequency of selected HLA alleles in two groups of transplant recipients: with 












All P-values correspond to the HLA in the corresponding row, SPSS software was 
used to calculate the p values. 
 
 BKV viremia  
N=23 (%) 
No viremia  
N=15 (%) 
P value  
HLA-A1 
(%) 
6(26) 6(40) 0.7 
A2 6(26) 5(33) 0.8 
HLA-B8 2(8.6) 5(33) 0.2 
B44 14(60) 3(20) 0.02* 
B51 1(4.3) 1(6.6) 1 
HLA-DR1 6(26) 2(13) 0.6 
DR3 2(8.6) 2(13) 1 
DR4 7(30) 2(13) 0.3 
DR7 2(8.6) 4(26) 0.37 
DR11 1(4.3) 2(13) 0.5 
DR13 1(4.3) 4(26) 0.15 





Figure 5.6. Risk of BKV viremia 
The risk in the first two years post transplantation based on HLA-B44 status. Kaplan-Meier survival curves were generated for 
17 renal recipients with HLA-B44 and 20 without HLA-B44. Tick marks represent censored recipients. The p-value was 










Figure 5.7. Risk of BKV viremia  
The risk in the first two years post transplantation based on HLA-DR 15 status. Kaplan-Meier survival curves were generated 
for 13 renal recipients with HLA-DR15 and 24 without HLA-DR15. Tick marks represent censored recipients. The p-value was 




Table 5.4. Cox regression analysis of multivariant factors that associate with development of BKV 
viremia. 
 HR 95% CI P- value 
Age  0.46 .009-0.15 0.6 
Gender  0.42 0.63-1.12 0.08 
HLA-B44 0.296 0.11-0.73 .009 
HLA-DR15 0.44 0.18-1.08 0.07 
HLA-A2  0.51-3.20 0.59 
HLA-mismatch   0.28 
A 2.9 0.6-13.7 0.177 
B 2.3 0.06-27 0.489 
DR 0.18 0.22-1.5 0.115 






BKV viremia and progression of BKV nephropathy are crucial problems that could 
jeopardize the success of renal transplantation, as no functional antivirus therapy 
is yet available to prevent virus reactivation. The current effective treatment 
strategy is based on reduction of administering immunosuppressive therapies to 
retrieve immunity with care to avoid acute graft rejection (Borni-Duval et al., 
2013; H. H. Hirsch et al., 2006). Around 15-30% of the recipients developed BKV 
viremia and 1-10% developed BKVN and loss of the graft (H. H. Hirsch & 
Randhawa, 2013). However, BKV reactivation outcomes could be avoided with 
predictions based around the recipients’ pre-transplant risk factors as no BKV 
viremia risk factors have yet been identified. 
In this chapter, we investigated pre-transplant anti-BKV IgG antibody levels in 
relation to development of BKV viremia in the recipients within a period of two 
years post-transplant. Additionally, we studied the role of some HLA molecules in 
associating with pathogenesis of BKV reactivation, leading to disease. Finding a 
significant positive correlation between pre-transplant anti-BKV levels, HLA alleles 
and development of BKV viremia would be useful in predicting development of 
viremia.  
The first observation was that 94.0% of seropositive pre-transplant recipients who 
developed BKV viremia did so within the first year of transplantation. Additionally, 
no significant difference was observed in mean pre-transplant anti-BKV IgG titres 
in recipients who developed BKV viremia, BKPyAN and the control group. (H. H. 
Hirsch et al., 2002). Bohl et al concluded that pre-transplant seropositivity may 
not prevent BKV reactivation and viremia but may ease the severity of the 
infection (D. L. Bohl et al., 2008). 
Secondly, we observed that during the onset of BKV viremia, specific immunity 
was generated to BKV that resulted in an increase in anti-BKV IgG levels about 
two-fold in comparison to pre-transplant levels; this stayed constant even after 
virus clearance and reduction in treatment with immunosuppressive therapies. It 
is worth noting that this increase in the antibody immune response was generated 
despite the weak immune status of recipients after transplantation. Consequently, 




and not directly affected by changes in treatment with immunosuppressive drugs 
but could be affected by an increase in virus reactivation.   
After clearance of viremia, anti-BKV IgG levels unexpectedly increased and 
remained stable for more than a year post clearance in the viremia and BKPyAN 
groups, while it tended to decrease in the control group who never experienced 
viremia one-year following post-transplant. This could be explained by the effect 
of immune suppressive therapy because it is proposed to reduce the humoral 
immune response (D. L. Bohl et al., 2008; Keven et al., 2003; Smith et al., 1998)  
Finally, we undertook a short retrospective investigation into linking HLA alleles to 
risk factors of BKV pathogenesis in renal transplant recipients. HLA molecules are 
known to play an important role in immune activation after infection. In most viral 
infections, HLA molecules present virus peptides to T-cell receptors, which activate 
CD8+ specific cytotoxic cell responses that lead to specific killing of virus infected 
cells. Furthermore, CD4+ T-cells assist in the generation of effector CD8+ T-cells 
and activation of B-cells that produce virus specific antibodies. Alternatively, NK 
cells may kill virus-infected cells that have altered or down-regulated cell surface 
class I HLA molecules.  
In transplantation, HLA -A, B, DR are known as major transplantation antigens.  A 
match between the donor and the recipient at these loci increases the likelihood 
of graft survival, and the presence of reactive anti-HLA antibodies in recipients 
against donor lymphocytes is a major obstacle to kidney transplantation (Gebel, 
Bray, & Nickerson, 2003) . 
We noted that some alleles were frequent in the recipient population studied, such 
as HLA-A2, HLA-B44 and HLA-DR15. Several studies have suggested that some 
HLA alleles may promote development of BKV viremia in renal transplant 
recipients. Teutsch et al observed that recipients who were HLA-A28 and HLA-A68 
positive showed a higher risk of developing viremia (Teutsch et al., 2015). 
However, HLA-A9 and HLA-A*02 alleles in the donor and the recipient were 
reported to be associated with a significant increase of development of BKyVAN 
(Teutsch et al., 2015). Also, a study by Bohl et al found that the lack of HLA-C7 
in the donor was associated with a higher risk of developing sustained viremia, 
that was explained by HLA-C7 involvement BKV cellular response and antigen 




In the present work, we observed that the presence of HLA-B44 and HLA-DR15 
was significantly associated with an increased risk of viremia among the recipients. 
However, in an earlier study by Masutani, in 2013, it was observed that HLA-A2, 
HLA-B44 and HLA-DR15 in recipients were associated with lower risk of BKV 
viremia (Masutani, Ninomiya, & Randhawa, 2013). A possible explanation for 
these results may be that rejection resulting from an HLA mismatch leads to an 
increase in the prescribed dose of immunosuppressive drugs and hence reduction 
of the response to BKV, allowing for viral reactivation. Another possibility is that 
the ongoing rejection response indirectly results in virus reactivation. Another 
explanation would be in the typing methodology; in our study we used the 
molecular based typing known to be more specific than the serological typing 
whilst the other study used the serological typing method (Bozón et al., 1997). 
The drawback to serological typing is that HLA-A specificities known to be found 
mainly in non-Caucasian populations are not identified. Another possibility is that 
there were differences in the incidence of variant BKV virus strains in the different 
studies (Yu et al., 1997). 
An inherent increased risk in the development of BKyVAN in patients who were 
HLA-B44 or DR15 may also be because those alleles are not as efficient at 
presenting BK peptides to CD8+ or CD4+ T cells, respectively. This could be 
studied further by investigating theoretical binding affinities of immunodominant 


























6 BKV genotypes and its influence on development of BKV 
viremia in kidney transplant recipients.  
 
Introduction  
BKV infection is an asymptomatic virus infection that is mainly acquired in early 
age. The virus establishes latency in the urothelium with the transient presence 
of virus particles in the urine. 15-85% of the population excrete BKV in their urine, 
while up to 90% of the healthy population are found to be seropositive (W. A. 
Knowles et al., 2003). In the context of immunosuppression, or in case of 
insufficient immunity, latent BKV can reactivate in the kidney causing BKV viremia, 
renal stenosis and BKV disease in renal transplant recipients. BKPyVN or BKV 
disease is one of the serious problems that threaten 1-10% of renal transplant 
recipients and which can lead to the loss of the transplanted graft (H. H. Hirsch & 
Randhawa, 2013). Currently, the initial strategy in treating BKV reactivation in 
most renal transplant centres is periodic screening for virus DNA in recipient blood 
to monitor for elevation in viral load, and thereby reduce immune suppressant 
therapy in cases of confirmed BKV viremia.  
Based on the variable region that encodes for the VP1 protein, BKV has been 
previously classified into four different genotypes; genotype l, ll, lll, and IV (L. Jin, 
2001). Further, based on the DNA sequence variation several other subtypes and 
subgroups were identified; Ia, Ib1, Ib2, Ic, IVa1, IVa2, IVb1, IVb2, IVc1, and IVc2 
(Nishimoto et al., 2007; Zhong et al., 2009). BKV subtypes showed different 
geographical distributions; for example genotype l was found to be the most 
prevalent genotype worldwide (80%), followed by IV (15%) in Europe and Asia 
(Ikegaya et al., 2006; Zhong et al., 2009), while genotypes ll and lll were rarely 
identified (Ikegaya et al., 2006; Takasaka et al., 2004). A better understanding of 
virus subtypes and their prevalence in different regions is needed for 
distinguishing between the various subtypes and the relatedness to disease. 
Furthermore, this will provide information regarding quality of the diagnostic 





Many risk factors have been proposed to play a role in the development of 
BKPyVN, either donor related, recipient related or virus-related. Yet very little is 
known regarding BKV genotypes and the associated risks for disease progression 
within post-renal transplant patients. Here, we investigated the prevalence of BKV 
genotypes in renal transplant recipients with BK viremia and the association of 
particular genotypes to the development of viremia or BKVN disease using a new 
simple BKV genotyping method.  
 
6.1 Patient demographics 
Thirty-two patients who underwent a kidney transplant 2017-2020 and had 
experienced BKV viremia at least once post-transplant, in the Renal Transplant 
Department at the University Royal Hospital Liverpool were included in the study. 
Patients’ demographic characteristics are illustrated (Table 6.1). All patients were 
under maintenance immunosuppressive therapy receiving either Mycophenolate 
mofetil or Azathioprine in addition to Tacrolimus. Mean patient age was 55.8 years 
with 22 males and 10 females included. Underlying diseases diagnosed were 
polycystic kidney (n=3), obstructive urology (n=3), hypertension (n=5) and other 
(n=21). 
 
Table 6.1 Demographic data of recipients who developed BKV viremia after transplant. 
Patients’ characteristic Values 




Polycystic kidney 9.3 











6.2 BKV genotyping in viremic renal transplant recipients 
In total 32 renal transplant recipients who developed BKV viremia within the first 
year of transplant were studied, urine or serum samples with confirmed BKV 
viremia were collected retrospectively. BKV DNA was isolated, and 28 samples 
were successfully amplified using a nested PCR (Fig. 6.1). The amplified DNA was 
subsequently sequenced using Sanger sequencing methodology. The analysis 
revealed that 6 (21.4%) of samples were genotype l-b1, and 22 (78.5%) were 
genotype l-b2 and none were identified with genotypes ll, lll or lV (Table 6.2). 





Figure 6.1.  Gel electrophoresis  
Showing amplification of the VP1 gene of BKV DNA using nested PCR, where the bands illustrate amplified DNA from 
recipients’ samples, 100bp ladder and negative controls. 
 
 






Table 6.2. BKV genotypes in urine and plasma of recipients with viremia after transplant n=32.  
The table shows each sample`s ID, viral load log10 copies /ml, amplification result, type of sample 
and genotype. 






 Algorithm Phylogenetic 
tree 
1 3.17 pos plasma Ib-2 Ib-2 
2 2.87 pos plasma Ib-2 Ib-2 
3 3.4 pos plasma Ib-2 Ib-2 
4 3.39 pos plasma Ib-2 Ib-2 
5 4 pos plasma Ib-1 Ib-1 
6 3.8 pos plasma Ib-1 Ib-1 
7 5 pos plasma Ib-2 Ib-2 
8 2.39 pos plasma Ib-2 Ib-2 
9 2.39 pos plasma Ib-2 Ib-2 
10 2.39 pos plasma Ib-1 Ib-2 
11 2.39 pos plasma Ib-2 Ib-2 
12 3.8 pos urine Ib-2 Ib-2 
13 4.5 pos urine Ib-1 Ib-1 
14 4.8 pos urine Ib-2 Ib-2 
15 2.3 pos plasma Ib-2 Ib-2 
16 3.9 pos urine Ib-2 Ib-2 
17 4.9 pos urine Ib-2 Ib-2 
18 5.9 pos urine Ib-2 Ib-2 
19 8.9 pos urine Ib-1 Ib-1 
20 6.1 pos urine Ib-2 Ib-2 
21 3.47 pos urine Ib-2 Ib-2 
22 3.9 pos urine Ib-2 Ib-2 
23 5.6 pos urine Ib-1 Ib-1 
24 2.3 pos plasma Ib-2 Ib-2 
25 3.2 pos plasma Ib-1 Ib-1 
26 2.3 pos plasma Ib-2 Ib-2 
27 2.3 pos plasma Ib-2 Ib-2 






6.3 Viremia versus genotype 
The association between peak viral load and BKV subtypes was analysed; mean 
BKV viral load from plasma samples for each genotype was as follows: genotype 
Ib-1 was 3.6 log10 copies/ml ± 0.24, range from (3.2-4 log10 copies /ml) and mean 
2.7 log10 copies /ml ± 0.2, range from (2.3-5 log10 copies /ml) for genotype Ib-2; 
p=0.07 for difference between the two genotypes. Mean viral load from urine 
samples was 6.2 log10 copies /ml ± 0.9 and ranged from (4.5-8.9) for Ib-1 
genotype and 4.4 log10 copies /ml ± 0.3, range from (3.8-6.1 log10 copies /ml) for 
Ib-2 genotype; p=0.055 for difference between the two groups as shown (Fig. 
6.2). Only two of the viremic patients developed BKPyVN with a mean BKV viral 
load of 2.3 log10 copies /ml, both of them were genotype lb 2.  Among our tested 







Figure 6.2. Renal transplant recipient`s BKV genotypes 
Genotypes in relation to viral load (log10 copies/ml) in urine A and plasma B samples. Horizontal bar represents mean viral 
load between the tested groups, p value was calculated using student’s t-test 
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Table 6.3.BKV genotypes and occurrence of BKV infection and disease. 
P value was calculated using student’s t -test or chi-square test 
 
Variables Genotype Ib-1 Genotype Ib-2 P-
value 
Age (mean) 54.4±14 56.7±15.3 0.7 
Sex (%) 6(19.3) 25(80.6) 0.5 
Male  3(50) 18(72)  
Female 3(50) 7(28)  




6.2 ± 0.9 4.4 ± 0.3 0.055 
BKviremia 
(Log10copies/ml) 
3.6±.24 2.7±.02 0.07 
BKPyVN 0 2 NS 
 
 
6.4 Validation of BKV algorithm and BKV phylogenetic tree. 
Performing BKV subtyping was mainly based on a phylogenetic tree analysis of 
the VP1 fragment, nucleotides (1564-2215) and the Large T antigen nucleotides 
(3021-3715). However, in this study we compared the previous method with a 
new simple and reliable strategy for BKV genotyping, where the method is based 
on amplification of only a 100bp segment of BKV VP1 from nucleotides 1977-2076 
(BK Typing and Group region (BKTGR (Morel et al., 2017). Following Sanger 
sequencing of the purified amplicon the sequences were manually reviewed and 
applied to the given new algorithm. 
All 28 sequences were aligned along with 40 complete BKV sequences retrieved 
from GenBank. A phylogenetic tree was constructed in order to cluster the strains 
based on BKV subtypes (Fig. 6.3). Our unknown sequences were 6 sample under 
lb-1 subtype and 22 samples under lb-2 subtype. The retrieved reference 




lll (n=5) and ll (n=4) subtypes. Next, we determined our sequences’ subtypes 
based on the 100bp BKTGR scheme (Fig 6.4 and 6.5). Comparing the two 
methods, a 98% (67 sample) similarity of the subtypes was obtained. Only one 






















































Genotype IB2 JN793998 1 BKV HSCT11 VP1 IB2 DQ989803 1 BKV PittVR5
type IB2 DQ989795 1 BKV PittVR1BKV14
BKV-1
Genotype IB2 AB263915 1 BKV DNA ESP 2
BKV-RLBKV6BKV25
Genotype IB2 JX195567 1 BKV VP1M11 VP1
Genotype Ia  JF894228 1 BKV BKV D
Genotype Ia  V01108 1 Human BK virus Dunlop
Genotype Ia  AB369092 1 BKV DNA A 62H
Genotype Ia  DQ989812 1 BKV PittVR4
Genotype Ia  DQ989807 1 BKV PittVR9
Genotype Ia  DQ989802 1 BKV PittNP4














































































































































































Genotype IV  JN
794002 1 BKV K
T30 VP1Genotype IV  KF468291 1 BKV d 60 VP1 VP1
Genotype IV  JN794010 1 BKV KT27 VP1
Genotype IV  AB269846 1 BKV DNA MON 1
Genotype IV  AB211391 1 BKV DNA TW 3
Genotype IV  AB211389 1 BKV DNA RYU 3
Genotype IV  AB365171 1 BKV DNA SHA 43
Genotype II  AB263920 1 BKV DNA GBR 12
Genotype II  KF468295 1 BKV d 151 VP1 VP1
Genotype II  AB301101 1 BKV DNA J2B 11
Genotype II  AB263916 1 BKV DNA ETH 3
Genotype III AB211386 1 BKV DNA KOM 3
Genotype III JN192440 1 BKV SJH LG 310
Genotype III KF055892 1 BKV KT 867 USA
Genotype III JX195577 1 BKV VP1M21 VP1





Figure 6.3. Maximum likelihood Phylogenetic analysis tree 

















Here we aimed to investigate any associations between BKV genotypes and 
development of BKV viremia or BKVAN in renal transplant recipients. The samples 
were sequenced and aligned with BKV complete genome sequences obtained from 
the literature to evaluate genetic diversity using a genotyping method based on 
amplification of only 100bp from the BKV VP1 gene. 
We reported the prevalence of BKV genotypes in a cohort of renal transplant 
recipients. Our data show that most of the viremic renal transplant recipient were 
infected with BKV genotype I with the highest proportion (78.5%) categorised 
under subtype I-b2 and substantially fewer categorised under subtype I-b1 (21.3 
%). Also, it is implied that there is no association between BKV genotype and 
development of BKV viremia in renal transplant recipients. 
These findings are found to be in concordance with a previous study showing the 
distribution of BKV genotypes in other European populations; subtype Ib-2 was 
most frequently detected in European and American populations, while Ic subtype 
was predominantly identified in the Asian population. The subtype IV distribution 
was variable among Asian, American and European populations (Zheng et al., 
2007) (Ikegaya et al., 2006; Zhong et al., 2009). No other genotype was detected 
in our study and could be explained by the fact that our participants were from 
the Liverpool area, where 91% of population are of Caucasian European ethnicity. 
Additionally, the limited sample size may have impacted on the findings. Also, we 
should keep in mind our study group were patients who experienced BKV viremia 
at least once post-transplant, as some other excluded patients who had low viral 
loads could be infected with other genotypes.  
Some virus genotypes, such as CMV gp1 subtype, have been reported to influence 
the course of disease after renal transplant (E. Nogueira, Ozaki, Tomiyama, 
Camara, & Granato, 2009). Additionally, HCV virus genotype 1 has been correlated 
with clinical outcome of disease in immunocompromised patients  (Núñez & 
Soriano, 2005). Our data suggest no specific association between BKV genotype 
and intensity or development of BKV viremia in renal transplant recipients. 
Furthermore, the two reported patients who developed BKPyAN were from 
genotype Ib-2. The same observation was reported for relation of BKV infection in 




provides further support to the hypothesis that progressive BKV disease after 
transplant is not associated with specific genotype, but the strength of cellular 
immunity induced against the virus (H. F. Wunderink et al., 2019). 
However, a study by Varella et al, proposed specific association between BKV 
subtypes and BKV viruria, as recipients infected with the la genotype exhibited 
higher viral load over others infected with lb genotype (Baksh et al., 2001; R. B. 
Varella et al., 2018; Yogo et al., 2009). Recently, Korth demonstrated a 
remarkable correlation (P=0.007) between BK genotype II and IV compared to 
genotype 1 and III (Korth et al., 2019). The point here is that in our cohort group 
we were not able to detect genotype Ia which weakens the comparison between 
the two findings. Moreover, other studies suggested that some genotypes have 
different viral replication kinetics compared to others, for example subtype l has 
been shown to replicate more efficiently in cell culture than other tested subtypes 
and subtype Ib-1 replication shows lower viral loads when compared to subtype 
Ib-2 (Drew, Walsh, Laoi, & Crowley, 2012; Nukuzuma et al., 2006; Tremolada et 
al., 2010).  This leads us to the concept that each genotype has diverse biological 
properties that may influence virus resistance and reactivation.  
Until recently, BKV genotyping has been based on phylogenetic analysis, and 
availability of a simple subtyping method provides clear information regarding 
association with BKV disease. For BKV genotyping, initially, our obtained sequence 
subtypes were identified according to generating a phylogenetic tree. Here we 
validated the identified subtypes using a new simplified method, based on a 100bp 
fragment (BKTGR). After the comparison between the phylogenetic analyses using 
the new algorithm, our data demonstrates 98% concordance. Only one sample 
demonstrated a difference in predicted genotypes between the two methods.  The 
possible explanation of this discordance that the new algorithm failed to 
differentiate  subtypes in samples with mixed infection (Morel et al., 2017).  
Several strategies were proposed for BKV subtyping; a study developed a BKV 
subtyping method based on high resolution melting analysis (Matsuda, Qazi, & 
Iwaki, 2011), but which failed to distinguish between strains with the same 
polymorphism. Further, Gard et.al proposed a real time PCR technique for BKV 
subtyping in bone marrow recipients, based on amplification of the virus VP1 gene 




as the used assay was unable to differentiate between strains with same amount 
of SNPs (Gard, Niesters, & Riezebos-Brilman, 2015). 
The most notable limitation of this study is the small sample size due to 
discounting follow up of some of the renal recipients in the main hospital. 
Additionally, we were not able to detect all BKV genotypes such as the lV subtype, 
which could be due to variations in the geographical distribution of genotypes with 
low frequencies locally. Larger regional studies could be performed with patients 
from different geographical areas to confirm our findings, however, from the 
results presented it is apparent that the genotype Ib-2 is the most prevalent in 
the Liverpool area.  
To conclude, our data reveals no significant differences between viral genotype 
and viral loads. No association was found between BKV genotype and disease 
progression in renal transplant recipients. Larger and prospective studies will be 
required to gain a better understanding and evaluation of BKV subtypes with the 

































Even though BKV infection is normally an asymptomatic infection in 
immunocompetent subjects it can lead to serious complications and even graft 
loss in renal transplant recipients due to the administration of immunosuppressive 
treatments, and lack of antiviral treatments. Therefore, better understanding of 
the host immune responses controlling the virus and the risk factors that influence 
BKV disease progression will be invaluable when aiming to avoid disease 
progression in post-transplant recipients.    
In this thesis we aimed to understand the host immune responses that are induced 
against BKV infection in healthy populations and renal transplant patients. Our 
aims were to study both cellular and humoral immune responses induced against 
BKV in different study categories, such as healthy individuals with or without 
detected virus and renal transplant recipients with or without post-transplant 
viremia. A further aim was to link specific HLA genotypes with disease outcome 
and severity to identify host restriction factors that control disease. 
As an initial objective of our project, we evaluated the cellular immune response 
against BKV peptides using an ELISPOT assay to measure INF-γ secreting T-cells 
in both study groups. Further, to measure the impact of BKV infection on the 
immune cells, induction of both sHLA-G and cell surface HLA-G expression 
following infection were studied. Flow cytometry was used for cell phenotyping 
and measurement of cell surface HLA-G protein expression levels. The proportions 
of HLA-G+ cells were estimated in various PBMC subpopulations including 
CD3+CD4+, CD3+CD8, CD19, CD14+HLA-DR+ and CD3+CD56+ cells, along with 
isotype control as cut off and unstimulated cells as negative controls. The third 
part of this thesis was evaluating humoral immune responses in renal transplant 
patient; pre-transplant anti BKV IgG, serostatus and activity were compared to 
post transplant in cases with or without development of BKV viremia. Lastly, BKV 
virus genotype prevalence in renal transplant patients were demonstrated and 
their relation to development of BKV viremia was investigated using a new simple 





7.1   BKV specific IFN-γ immune responses and antibody 
responses in healthy subjects and renal transplant 
recipients. 
In order to evaluate post-transplant immune responses against BKV viremia and 
the mechanism of virus clearance we measured BKV specific IFN-γ secreting cell 
responses using an ELISPOT assay in a cohort of healthy subjects and kidney 
transplant recipients with various statuses of BKV. 
BKV shedding in urine of healthy individuals and renal transplant recipients was 
measured as our first objective in BKV screening, due to its high sensitivity and 
early detection compared to that expected in plasma. However, detection of virus 
DNA in urine doesn’t necessarily reflect BKV infection and induction of immune 
responses. Individuals who become infected with BKV may not completely 
eliminate virus but may continue to shed virus in the absence of any pathological 
effects. Therefore, BKV serological status was further tested, as an indicator of 
previous BKV infection. Those individuals who tested positive for BKV IgG, were 
tested for BKV DNA in urine. Those individuals identified with positive antibody 
responses would be expected to also harbour CD4 T cell responses which are 
required to induce antibody responses. The comparison of cellular immune 
responses was therefore based on BKV positive serological status (IgG) and not 
only DNA excretion in urine. Given this, it would have been relevant to have tested 
individuals who were anti BKV IgG (+) for cellular responses even though they did 
not show viral shedding in urine. 
 
After comparison of virus cellular immune responses in healthy subjects and renal 
transplant patients, our data indicated that healthy subjects had a higher cellular 
response than patients, irrespective of BKV status. Regarding the patient groups 
with different BKV status; T-cell response results were highest in the group who 
never had BKV, followed by the historical BKV (+) group. Here, high responses 
could suggest strong BKV-specific immunity in the negative group and recovery 
of BKV-specific immunity after BKV replication in the historical patients. It is 
possible that patients who were BK negative had previously encountered the virus 




be consistent with their strong immune response. On the other hand, low level of 
cellular immune responses in the BK viremia group can implicate impaired BKV-
specific immunity at the time of viremia, which is   more likely due to the 
immunosuppressive therapies that transplant individuals receive in order to 
dampen immune responses and prevent acute graft rejection, however the cellular 
response was restored.   
Next, we measured anti-BKV IgG levels in the same groups. In the healthy group 
no significant differences were observed between anti BKV IgG (+), urine (+) and 
anti BKV IgG (-) urine (-) subjects. Again, this may be because some apparently 
virus negative subjects had reduced virus secretion into urine to undetectable 
levels. In contrast, patient groups showed significant differences based on BKV 
status. A significant difference was found between pre- and post-transplant 
patients who developed viremia. Also, anti BKV IgG levels were significantly higher 
in patients who cleared the virus than those who never experienced infection. 
Interestingly, a significant negative correlation was observed between BKV viral 
load and anti-BKV IgG levels as well as elevation of the IgG levels post-transplant. 
This has implications regarding the role BKV specific humoral immune responses 
play in controlling viral replication as the increase in the negative group was not 
significantly different from that observed pre-transplant. 
A caveat with interpreting the anti-BKV antibody results is that modification of a 
semi-quantitative test was utilised. It was therefore difficult to determine a clear 
cut-off point between anti-BKV antibody +ve and -ve subjects. This contrasts with 
the experience of CMV in our laboratory which always showed a clear 
discrimination between antibody +ve and -ve sera (Albayati et al, 2018). This may 
result from CMV stimulating stronger antibody responses than those induced in 
BKV infected individuals.    
We demonstrated that the BKV-ELISPOT assay may facilitate in predicting the 
progression of BKV infection; BK virus specific IFN-γ immune response was higher 
in patients who cleared BKV infection post-transplant. Also, the results were 
significantly lower in patients who showed development of BK viremia. As samples 
were taken at time of viremia, it is likely that sufficient time had not elapsed for 
an effective immune response to be mounted. Our study is limited with a relatively 




serostatus and neutralizing antibody was not available, which is believed to 
correlate with post-transplant viremia (Abend et al., 2017; Bae et al., 2020b; Solis 
et al., 2018). Future studies on the current topic are therefore recommended with 




7.2 Induction of human leucocyte antigen G (HLA-G) in response 
to BKV peptide stimulation in healthy subjects and renal 
transplant recipients. 
Here, we hypothesized that BKV infection is influencing HLA-G expression on some 
lymphocyte subsets and modulating cells’ action as BK virus escape strategy to 
evade immune responses. It has been suggested that CMV infection upregulates 
HLA-G molecules during infection which can inhibit NK cell activation, critical in 
restricting viral spread (Wilkinson et al., 2008). More recently, our group has 
shown that CMV can upregulate HLA-G expression on a range of leucocyte subsets, 
predominantly CD56+ T-cells and B-cells (Albayati et al., 2018).  
We demonstrated HLA-G expression on groups of PBMCs isolated from healthy 
subjects with or without BKV and renal transplant recipients with viremia or who 
never had viremia. It was observed that culturing the cells of BKV negative healthy 
subject with BKV peptides slightly increased the expression of HLA-G, especially 
on monocyte populations in the healthy group. These results reflect findings of 
previous studies where it was found that low levels of HLA-G+ cells are to be found 
in healthy subjects (Lozano et al., 2002; Feger et al., 2007). This was unexpected 
as HLA-G is mainly limited to the feto-maternal interface and it plays a role in 
preventing maternal immune reactions against foetal tissues (Rebmann, da Silva 
Nardi, Wagner, & Horn, 2014). Our results demonstrate that culturing PBMCs with 
BKV peptides induced a slight induction of HLA-G on monocyte populations of both 
BKV (+) and BKV (-) healthy subjects. However, other lymphocyte subsets such 
as CD3+CD4+ and CD3+CD8+ cells showed very low levels of expression. 
In renal transplant patients, a slight up-regulation of HLA-G expression was 




which is in agreement with previous findings which reported low levels of 
expression of HLA-G on CD8+ T-cells in peripheral PBMCs from renal allograft 
recipients (Lu et al., 2011; Xiao et al., 2013). Finally, after measuring induction 
of HLA-G in healthy subjects and renal recipients with BKV virus viremia, it was 
clear that patients with BKV virus viremia showed higher percentages of HLA-G 
on all the lymphocytes subsets. However, it is important to note that upregulation 
of HLA-G could be due to the influence of immunosuppression as all our patients 
are under immunosuppressive therapy administration, which is known to have an 
indirect effect on HLA-G via increasing cytokine production such as IL-12, IL-10, 
and IL-4 by activated T-helper cells (Daniel et al., 2005). In future work a larger 
follow up study should be conducted with renal transplant recipients in different 
stages of BKV viremia. Also investigating the influence of immunosuppressive 
therapy on cultured lymphocytes with BKV peptides in vitro would likely be 
revealing. Further, additional approaches must be used to overcome the limitation 
of flow cytometry data analysis, through using multicolour flow cytometry to 
increase the information from each cell sample.  
  
 
7.3 sHLA-G concentrations in healthy subjects and renal 
transplant recipients. 
The presence of sHLA-G in serum of either liver or kidney transplant recipients 
has raised the hypothesis that its presence has an association with immune 
suppression and preventing acute graft rejection (Lila et al., 2002). The role of 
sHLA-G in virus infection is apparent with its ability to bind KIR2DL4 on PBMCs, 
especially NK cells, and produce pro-inflammatory and angiogenic cytokines  (Van 
der Meer et al., 2007) as well as induce apoptosis in CD8+ lymphocytes and NK 
cells and thereby inhibit T-cell responses (Fournel et al., 2000).   
Our data revealed that no significant difference was observed in plasma sHLA-G 
levels in healthy subjects with BKV Ab, either with BKV DNA or without. The same 
observation was reported in the patient groups as no difference was found 
between patients with BKV viremia and those who never had viremia. However, 
sHLA-G levels were found to be higher in renal transplant patients in comparison 




immunosuppressive therapy but also does not exclude the influence of BKV on 
inducing immune evasion as most of our viremic patients were undergoing a 
reduction in their immunosuppressive therapy regime in order to prevent virus 
replication through increasing induced immunity.    
 
7.4 BKV pre- and post-transplant IgG responses in renal 
transplant receipts  
Evaluating risk factors that may influence BKV reactivation and development of 
viremia could lead to an early diagnosis of patients at risk for BKPyAN, and 
consequently preventive treatment, that may improve disease outcome (Buehrig 
et al., 2003; H. H. Hirsch et al., 2002). Pre-transplant and pre-viremia evaluation 
of BKV humoral immune responses would help in understanding whether high anti-
BKV titres pre-transplant or during viremia could protect from or prevent BKV 
disease development and if recipients with high risk could be monitored closely 
with appropriate intervention. 
Our data showed that pre-transplant anti BKV levels were similar in patients with 
BK viremia and those who never had BKV viremia, which concurs with previous 
studies which  found that pre-transplant seropositivity did not prevent BK viremia 
or was even considered as a risk factor for BKPyAN (D. L. Bohl et al., 2008; H. H. 
Hirsch et al., 2002). Another study demonstrated elevation of BKV viremia in 
seronegative patients (Sood et al., 2013). This raises the question as to whether 
serum anti-BKV IgG could effectively protect against BKV infection in the 
urothelium and whether local levels of specific secretory IgA or IgM may be more 
relevant. This would be difficult to investigate directly, but specific antibody levels 
in secretory fluids such as nasal or lachrymal secretions may be more relevant, 
representing secretions at other mucosal sites.    
After following up evaluation of three different samples from each patient during 
different periods of BKV reactivation; pre-transplant, viremia and post viremia, we 
found that levels of virus-specific IgG antibodies were relatively low pre-
transplant, however, they significantly increased with development of the viremia 
in parallel with the reduction of the immunosuppression therapy. The levels of 
humoral immune responses remained high even after the clearance of viremia. 




some patients may be a result of a slower or weaker virus-specific secretory 
antibody response in these individuals. On the other hand, in patients who never 
experienced an episode of BKV viremia after transplant the level of anti-BKV IgG 
responses were found to be steady pre- and post-transplant. Our data confirmed 
the observations of Pastrana et al. that patients receiving immunosuppressive 
therapies can still develop efficient humoral immune responses (Pastrana et al., 
2013). 
The above findings could be limited by the relatively low number of evaluated 
patients. Also, unavailability of a standardized, fully quantitative serological assay 
for anti-BKV IgG may have led to some variability within the assays and less 
reliable quantification of differences in antibody titres. Furthermore, the ELISA test 
used was against VP1 antigen only, but it is unknown if antibodies against other 
BKV antigens would yield the same results. Additionally, pre-transplant 
seropositivity does not necessarily mean development of BKV specific memory T-
cells that are necessary to control BKV reactivation, it could be result of a patient’s 
contact with the virus previously (P. Comoli et al., 2004).  
 
7.5 Risk of BK Infection in HLA-A02, B44 and DR15–positive 
Kidney Transplant Recipients. 
MHC molecules play an important role in antigen presentation to immune cells and 
in the generation of T-cell responses. Briefly, after viral infection, viral peptides 
are presented by MHC class-II and interact with CD4+ cells to generate T-helper 
cells that aid in the generation of cell mediated immunity by the activation of 
CD8+ cells and activation of B cells for virus specific antibody production. MHC 
class-I presentation of antigen activates CD8+ T-cells to produce virus specific 
cellular response by generating cytotoxic T-cells which can eliminate virally 
infected cells expressing the antigen as well as T cell memory (Rouse & Mueller, 
2019). So, identification of alleles of MHC molecules that influence progression of 
BKV infection may help in predicting BKV reactivation risks in KTR individuals prior 
to transplantation and predict development of viremia after transplant.  
Here we investigated the effect of some HLA alleles in the development of BKV 
viremia in kidney transplant recipients. Certain alleles were found to be associated 




Rao, Hoof, van Baarle, Keşmir, & Textor, 2015). We evaluated some common HLA 
alleles such as HLA-A02, HLA-B44 and HLA-DR 15 and their association with BKV 
viremia in the recipients. It was observed that the presence of HLA-B44 and HLA-
DR15 were significantly associated with increased risk of viremia among the 
recipients which differs from previous findings who demonstrated the influence of 
particular HLA alleles in reducing the risk of BKV viremia (Masutani et al., 2013; 
Herman F Wunderink et al., 2019). A possible explanation for this contradiction is 
the difference in the HLA typing methods used to determine genotypes among the 
transplantation centres. Additionally, an understanding of the importance of the 
clinical role of HLA alleles in influencing virus infections is not clear and the need 
to initiate studies with uniform viral load screening strategies in viremic patients, 
without interference of immunosuppressive therapy, would be highly informative. 
Furthermore, although, this study is one of the few on the impact of HLA alleles 
on BKV viremia in KTR; our study is limited with regards to its retrospective nature 
that it is based in a single centre and considering that the sample size was 
relatively small, particularly in the BKV+ control group. These findings need to be 
confirmed by larger prospective studies involving multiple centres.  
 
 
7.6 Association of BKV genotypes in development of BK viremia  
Finally, we aimed to investigate the BKV genotype prevalence in renal transplant 
patients and to evaluate whether BKV genotypes could associate with 
development of BKV viremia in post renal transplant recipients retrospectively. 
Our data indicated that all our tested groups were infected with BKV subtype I; 
78.5% of the tested group were infected with subtype I-b2, while 21.4% were 
infected with subtype I-b1, the two most common BKV subtypes in the UK, 
although there is some geographical variation with other subtype predominating 
in different parts of the world.  
No significant correlation was observed between the genotypes and BKV viremia, 
which contrasts with previous literature reporting an association between viral 
subtypes and development of disease after transplant, with the first two studies 
reporting on CMV subtypes (Eliana Nogueira, Ozaki, Tomiyama, Câmara, & 




2018). This inconsistency could be due to variability of the viral load quantification 
between transplant centres, such as variability of using different controls to 
measure copy number and different primers and probe assays that are highly 
important in detection of BKV genotypes. 
BKV subtyping and subgrouping were based mainly on phylogenetic analysis which 
is less discriminating than when the analysis is based on the 327bp region used in 
some BKV-typing studies (Trofe-Clark et al., 2013). However, our genotyping 
method was based on analysis of only 100bp of the VP1 gene to permit 
discrimination between subtypes and subgroups (Morel et al., 2017). 
An important future recommendation would be the adoption of a genotyping 
method that is simple and accessible to routine laboratories, to better understand 
virus related factors that lead to BKV disease progression. The notable limitation 
of this study is the small sample size; due to limited follow up in the renal 
transplant recipients in the hospital which may have restricted us being able to 
detect the other BKV genotypes, such as subtype IV, although this could also be 
due to variant geographical distributions of these genotypes. Furthermore, the low 




In this work it has been shown that immunocompetent subjects with BKV detected 
in their urine were able to mount specific BKV cellular immune responses, which 
were deficient in KTR individuals who developed viremia, but these immune 
responses were found to be restored after resolving viremia. This leads to the 
conclusion that control of BKV replication in KTR individuals is highly correlated 
with the generation of BKV-specific cellular immune responses. 
HLA-G expression has been suggested to have a negative role in virus evasion 
from the development of host immune responses and in cancer development 
(Amiot, Vu, & Samson, 2014b), but also it was found to be beneficial such as in 
aseptic shock (Monneret et al., 2007). The role of this molecule in modulating 
immunity requires further investigation as it is still not clear whether it is related 




highly beneficial in utilising HLA-G parameters as a therapeutic marker when 
treating BKV infection in KTR individuals, Also, we showed that IgG responses to 
BKV infection was stable in healthy subjects, whilst in BKV (+) transplant patients 
was mainly influenced by virus replication (viremia). However, using pre-
transplant anti-BKV IgG levels as a biomarker for predicting BKV infection is not 
sufficient, and a patient’s sero-reactivity should be considered when seeking a 
more accurate prediction of outcome. 
Finally, BKV genotype lb-2 was found to be the most dominant genotype among 
our patients with no direct influence of specific genotype being associated with 
increased risks of viremia or development of BKV disease. 
 
7.8 Future directions  
BK virus infection has become one of the most recognizable obstacles in solid 
organ transplant, especially kidney transplant and in hematopoietic stem cell 
transplant recipients due to influence of immunosuppression regimens. Despite 
the current detection and screening methods after transplantation, an extra focus 
on the pre-transplant factors must establish, for example, a pre-transplant 
algorithm or risk assessment that may help deciding the best approach in treating 
the recipients after transplantation. By studying some pre-transplantation risk 
factor such as donors seropositivity, donor-recipient HLA mismatching, and other 
virus-related factors like serotypes and genomic mutations and measuring 
humoral immunity against the other BKV genotypes for better prediction and early 
elimination of the virus replication before the disease progression. 
As there is no specific antiviral treatment for BK viremia, there is an urgent need 
of randomized multicentre clinical trials that investigates the reasons of activation 
of the virus in some patients but not others, and the immune response toward the 
virus replication and disease progression. Also, there is a crucial need of testing 
and evaluating some anti-viral combination therapies that may help in elimination 
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